



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/29, 15/82, C07K 14/415, G01N 33/53, A01N 65/00, A01H 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/64599</p> <p>(43) International Publication Date: 16 December 1999 (16.12.99)</p>						
<p>(21) International Application Number: PCT/CA99/00532</p> <p>(22) International Filing Date: 8 June 1999 (08.06.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 33%;">2,235,978</td> <td style="width: 33%;">8 June 1998 (08.06.98)</td> <td style="width: 33%;">CA</td> </tr> <tr> <td>2,256,121</td> <td>31 December 1998 (31.12.98)</td> <td>CA</td> </tr> </table> <p>(71) Applicants (for all designated States except US): AGRICULTURE AND AGRIFOOD CANADA [CA/CA]; Saskatchewan Research Centre, 107 Science Dr. Place, Saskatoon, Saskatchewan S7N 0X2 (CA). UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. [CA/CA]; The University of Saskatchewan, Kirk Hall, Room 304, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). NATIONAL RESEARCH COUNCIL OF CANADA [CA/CA]; 1200 Montreal Road, Ottawa, Ontario K1A 0R6 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): WANG, Hong [CA/CA]; Agriculture and Agrifood Canada, Saskatchewan Research Centre, 107 Canada Place, Saskatoon, Saskatchewan S7N 0X2 (CA). FOWKE, Larry, C. [CA/CA]; The University of Saskatchewan, Dept. of Biology, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). CROSBY, William,</p>	2,235,978	8 June 1998 (08.06.98)	CA	2,256,121	31 December 1998 (31.12.98)	CA	<p>L. [CA/CA]; 202 Dore Crescent, Saskatoon, Saskatchewan S7K 4X9 (CA).</p> <p>(74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar, Vancouver Centre, 2200-650 W. Georgia Street, Box 11560, Vancouver, British Columbia V6B 4N8 (CA).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
2,235,978	8 June 1998 (08.06.98)	CA						
2,256,121	31 December 1998 (31.12.98)	CA						
<p>(54) Title: CYCLIN-DEPENDENT KINASE INHIBITORS AS PLANT GROWTH REGULATORS</p>								
<p>(57) Abstract</p> <p>The invention provides methods for using cyclin-dependent kinase (CDK) inhibitor genes, or anti-sense constructs complementary to such genes, to modify the growth and development of plant cells and organs. The invention provides methods of modifying the development of plant cells and plants by transforming plant cells with nucleic acids encoding cyclin-dependent kinase inhibitor polypeptides, or anti-sense constructs complementary to such nucleic acids, to produce transformed plant cells, and then culturing the plant cells or regenerating a plant under conditions wherein the cyclin-dependent kinase inhibitor, or the anti-sense constructs, is expressed. A variety of CDK inhibitor genes, and corresponding anti-sense constructs, are disclosed for use in a variety of plants. The nucleic acid encoding the cyclin-dependent kinase inhibitor may be operably linked to a tissue-specific promoter. Another aspect of the invention provides modified transgenic plants and plant tissues. The invention also provides methods of identifying nucleic acids that encode cyclin-dependent kinase inhibitors that are active in plants to modify the development of the plants.</p>								

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYCLIN-DEPENDENT KINASE INHIBITORS AS PLANT GROWTH REGULATORS

FIELD OF THE INVENTION

The invention relates to the modification of growth and development of plants
5 through transgenic sense or anti-sense expression of cyclin-dependent kinase inhibitor genes.

BACKGROUND OF THE INVENTION

In eukaryotes including plants, the progression of cell cycle events is regulated by a network of gene products and factors to ensure that this crucial process is initiated as an integral part of the growth and the developmental program, and in response to the external
10 environment. These factors exert their influences on the cell cycle machinery via various pathways. At the center of the machinery lies an enzyme complex consisting of a catalytic subunit, cyclin-dependent protein kinase (CDK), and a regulatory subunit, cyclin. CDKs are a group of related serine/threonine kinases and their activity generally depends on their association with cyclins (Pines, 1995).

15 Early work disclosed the existence of CDKs in yeast. A CDK called Cdc2 (p34^{cdc2}, or CDK1) was identified in fission yeast *Schizosaccharomyces pombe* (Hindley and Phear, 1984) and a Cdc2 homolog called CDC28 was identified in budding yeast *Saccharomyces cerevisiae* (Lőrincz and Reed, 1984). In yeast, Cdc2 (or CDC28) kinase appears to be solely responsible for regulating the progression of the cell cycle.

20 Animal cells have evolved several Cdc2-related CDKs in order to achieve more complex regulation at multiple levels. In mammalian cells, seven distinct CDKs and eight types of cyclins have been identified (see review by Pines, 1995). Complexes of these CDKs and cyclins appear to act sequentially at different checkpoints during the cell cycle, while incorporating the input of different developmental and environmental cues.

Plants, like higher animals, have multiple CDKs (Francis and Halford, 1995; Jacobs, 1995) and cyclins (Renaudin et al., 1996). In *Arabidopsis thaliana*, at least two Cdc2 homologues, Cdc2a and Cdc2b (Ferreira et al., 1991; Hirahama et al., 1991) and as many as twelve cyclins belonging to three groups (Renaudin et al., 1996) have so far been documented. Of the two Cdc2 homologues in *A. thaliana*, Cdc2a resembles more closely Cdc2 homologues from other species because it has a conserved PSTAIRE motif and is able to genetically complement yeast *cdc2* or *CDC28* mutants (Ferreira et al., 1991; Hirahama et al., 1991), indicating some functional homology of *A. thaliana* Cdc2a with the yeast Cdc2 kinase. Expression analyses showed that *A. thaliana cdc2a* expression was correlated with the "competence" of a cell to divide and preceded the re-entry of differentiated cells into the cell division cycle (Martinez et al., 1992; Hemerly et al., 1993), and expression of a dominant negative *cdc2a* mutant resulted in cell cycle arrest (Hemerly et al., 1995). *A. thaliana* Cdc2b is atypical in that it has a PPTALRE motif in place of the PSTAIRE motif. Like *cdc2a*, *cdc2b* is also expressed in dividing plant cells. While *cdc2a* is expressed constitutively throughout the cell cycle, *cdc2b* is reportedly expressed preferably in S and G2 phases (Segers et al., 1996).

Relatively little is known about the cyclins and other proteins and factors which regulate the activity of CDK-cyclin complexes in plant cells. Results from yeast and mammalian studies have demonstrated multiple pathways, both positive and negative, by which CDK activity can be modulated (Lees, 1995). In addition to binding by a cyclin, for example, activation of CDKs may also involve a CDK-activating kinase (CAK) which itself is a CDK, and CDC25 protein phosphatase.

A new aspect of regulating CDK activity was discovered with the identification of CDK inhibitors (see reviews by Pines, 1995; Sherr and Roberts, 1995; Harper and Elledge, 1996). These small molecular weight proteins are understood to bind stoichiometrically to negatively regulate the activity of CDKs. It has been suggested that these inhibitors may be involved in animal development and cancer, in addition to their role in cell cycle regulation (Harper and Elledge, 1996). A plant CDK inhibitor activity was observed and was suggested to be involved in endosperm development in maize (Grafi and Larkins, 1995).

The activity of CDK inhibitors has been studied in animals. Transgenic mice have been generated lacking p21, p27 and p57 CDK inhibitor genes. The p21 knockout mice are reported to develop normally but are deficient in G1 checkpoint control, such as cell cycle arrest in response to DNA damage (Deng et al., 1995). Analysis of p27 knockout mice from three independent studies show that transgenic mice lacking p27 display larger body size than control mice (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996). The enhanced growth is reportedly due to an increase in cell number (Kiyokawa et al., 1996) and is gene dose-dependent (Fero et al., 1996). In comparison, none of p21 or p57 knockout display enhanced growth. The transgenic mice lacking p57 show a range of developmental defects such as defective abdominal muscles, cleft palate and renal medullary dysplasia (Yan et al., 1997; Zhang et al., 1997). A few developmental defects were observed in p27^{-/-} mice. They include impaired ovarian follicles (thus female sterility), impaired luteal cell differentiation and a disordered estrus cycle. These results reflect a disturbance of the hypothalamic-pituitary-ovarian axis. In comparison, transgenic mice lacking p21 appear to develop normally at both gross anatomic and histologic levels (Deng et al., 1995). In addition, an increase in apoptosis is observed in mice lacking p57. The CDK inhibitor p27 was over-expressed in mouse hepatocytes (Wu et al., 1996), resulting in a general decrease in overall number of adult hepatocytes which result in aberrant tissue organization, body growth and mortality.

Despite the general conservation of basic cell cycle machinery in eukaryotes, the role of plant cell division during plant growth and development is characteristically different from other eucaryotic cells. In many respects, the regulation of plant cell division and growth can be regarded as distinct from other eucaryotic cells. For example, plant cells are not mobile during morphogenesis. Different sets of hormones are involved in modulating plant growth and development. Plant cells are remarkable for their ability to re-enter the cell cycle following differentiation. Also, cell division in plants is continuous, along with organ formation, and plant body size (the number of total cells and size of the cells) can vary dramatically under different conditions. Plants also have an inherent ability to incorporate additional growth into normal developmental patterns, as is illustrated by a study showing that ectopic expression of a mitotic cyclin driven by the *cdc2a* promoter resulted in a larger

but normal root system (Doerner et al., 1996). However, relatively little is known about the connections of the regulatory genes controlling cell division patterns to the cell cycle regulators such as the CDKs and the cyclins in plants (Meyerowitz, 1997).

A few studies of transgenic expression of cell cycle genes in plants are documented using various cell cycle genes other than CDK inhibitors. A heterologous yeast *cdc25*, a mitotic inducer gene, was introduced into tobacco plants under the control of a constitutive CaMV 35s promoter (Bell et al., 1993). Transgenic tobacco plants showed abnormal leaves (lengthened and twisted lamina, pocketed interveinal regions), abnormal flowers, and also precocious flowering. Analysis of cell size in the root meristem revealed that transgenic plants expressing the yeast *cdc25* had much smaller cells (Bell et al., 1993). The wild type *cdc2a* gene and variants of dominant negative mutations under the control of CaMV 35s promoter have been used to transform tobacco and *Arabidopsis* plants (Hemerly et al., 1995). Constitutive expression of wild-type and mutant *Cdc2a* did not significantly alter the development of the transgenic plants. For the dominant negative *Cdc2a* mutant, it was not possible to regenerate *Arabidopsis* plants. Some tobacco plants expressing this construct were obtained and they had considerably fewer but much larger cells. These cells, however, underwent normal differentiation. Morphogenesis, histogenesis and developmental timing were unaffected (Hemerly et al., 1995). As mentioned above, ectopic expression of an *Arabidopsis* mitotic cyclin gene, *cyc1At*, under the control of the *cdc2a* promoter increases growth without altering the pattern of lateral root development in *Arabidopsis* plants (Doerner et al., 1996).

The yeast two-hybrid system has been used to identify the cyclin-dependent kinase inhibitor gene *ICK1* from a plant (Wang et al., 1997). *ICK1* is different in sequence, structure and inhibitory properties from known mammalian CDK inhibitors. It has been shown that recombinant protein produced from this gene in bacteria is able to inhibit plant *Cdc2*-like kinase activity *in vitro* (Wang et al., 1997).

Cytotoxin genes, *i.e.* genes encoding a protein which will cause cell death, have been tested in transgenic plants for genetic ablation of specific cells or cell lines during development, including RNase (Mariani et al., 1990), DTT (diphtheria toxin) chain A

(Thorsness et al., 1991; Czako et al., 1992), Exotoxin A (Koning et al., 1992) and ribosomal inhibitor proteins (United States Patent No. 5,723,765 issued 3 March 1998 to Oliver *et al.*). Several disadvantages may be associated with the use of cytotoxin genes for modification of transgenic plants, particularly plants of agronomic importance. The action of the cytotoxin may not be specific and may result in non-specific destruction of plant cells. This effect may be the result of diffusion of the cytotoxin, or of non-specific expression of the cytotoxin gene in non-target tissues. Non-specific low-level expression of the cytotoxin may be a difficult problem to overcome, since most tissue-specific promoters have some levels of expression in other tissues in addition to a high level of expression in a particular tissue. Expression of a potent cytotoxin gene even at a low concentration may have a negative impact on growth and development in non-target tissues. The presence of cytotoxic proteins of transgenic origin may also have a negative effect on the marketability of an edible plant, or plant product, even if the cytotoxin is demonstrably benign to consumers.

15 SUMMARY OF THE INVENTION

The invention provides methods of modifying plant or plant cell development using CDK inhibitors. In the context of the invention, the word 'development' encompasses a wide variety of biological process, including growth, morphogenesis, multiplication, enlargement, differentiation or maturation of a cell. In one aspect, the methods of the invention involve transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, or an anti-sense construct complementary to such a nucleic acid, to produce a transformed plant cell; and, growing the transformed plant cell, or progeny of the transformed plant cell, under conditions wherein the cyclin-dependent kinase inhibitor polypeptide, or the anti-sense construct, is expressed in the transformed plant cell or in the progeny of the transformed plant cell. The growing of the transformed plant cell or progeny of the transformed plant cell may be carried out to produce a transformed plant, and the cyclin-dependent kinase inhibitor polypeptide, or anti-sense construct, may be expressed to modify the development of the transformed plant or progeny of the transformed plant.

In one embodiment, the invention provides methods for using CDK inhibitor genes to modify the growth and development of plant cells and organs. In particular, the invention provides a method of modifying the development of a plant comprising (*i.e.* having or including, but not limited to) transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor to produce a transformed plant cell. A plant may then be regenerated from the transformed plant cell under conditions wherein the cyclin-dependent kinase inhibitor is expressed during regeneration or growth of the plant to modify the development of the plant. The nucleic acid encoding the cyclin-dependent kinase inhibitor may be homologous to *ICK1*, or may be *ICK1*, respectively encoding a cyclin-dependent kinase inhibitor homologous to *ICK1* or *ICK1* itself. In particular embodiments, the plant may be *A. thaliana*, or a member of the *Brassica* genus, or a canola variety. The nucleic acid encoding the cyclin-dependent kinase inhibitor may be operably linked to a tissue-specific promoter, such as *AP3* or a promoter homologous to *AP3*. In particular embodiments, the tissue-specific promoter may mediate expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor in petal and/or stamen primordia, and the development of the plant may be modified so that the plant has altered petals and/or is male sterile.

Another aspect of the invention provides transgenic plants comprising (*i.e.* having or including, but not limited to) an expressible heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor, wherein the heterologous nucleic acid is introduced into the plant, or an ancestor of the plant, by the foregoing method. Alternatively, the plants may comprise a nucleic acid encoding a cyclin-dependent kinase inhibitor, and the plant cells may be transformed with an anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor, to produce a transformed plant cell. So that regenerating the plant from the transformed plant cell under conditions wherein the anti-sense nucleic acid is transcribed during regeneration or growth of the plant to inhibit the expression of the cyclin-dependent kinase inhibitor and modify the development of the plant. Plants of the invention may have a recombinant genome and the heterologous nucleic acid may be integrated into the recombinant genome. The invention encompasses plant tissues, such as seeds, comprising a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor,

or an anti-sense construct, that is expressed during the development of a plant from the tissue to modify the development of the plant.

The invention also provides methods of identifying nucleic acids that encode cyclin-dependent kinase inhibitors, such as nucleic acids homologous to *ICK1*, that are active in plants to modify the growth or development of the plants.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows cDNA (Wang et al., 1997) and genomic sequences of *ICK1*, wherein: (A) shows the genomic organization *ICK1*. Open bars represent exons and filled bars represent introns; (B) shows features of the cDNA sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2).

Figure 2 shows the alignment of *ICK1* cDNA sequence (SEQ ID NO: 3) with *ICK1b* (SEQ ID NO: 4) and *ICKc* (SEQ ID NO: 5).

Figure 3 shows the cDNA sequence of *ICK2* (SEQ ID NO: 6).

Figure 4 shows the cDNA sequence of *ICN2* (SEQ ID NO: 7).

Figure 5 shows the cDNA sequence of *ICN6* (SEQ ID NO: 8).

Figure 6 shows the cDNA sequence of *ICN7* (SEQ ID NO: 9); The nucleotide sequence of *Chenopodium rubrum* *CDKI1* (GenBank AJ002173, SEQ ID NO. 15); and, The amino acid sequence of *Chenopodium rubrum* *CDKI1* (SEQ ID NO. 16).

Figure 7 shows the alignment of deduced amino acid sequences of *ICK1* (SEQ ID NO: 10), *ICK 2* (SEQ ID NO: 11), *ICN2* (SEQ ID NO: 12), *ICN6* (SEQ ID NO: 13), and *ICN7* (SEQ ID NO: 14), and a resultant consensus sequence.

Figure 8 shows deletion mapping in the yeast two-hybrid system of functional regions of ICK1 involved in interactions with Cdc2a and CycD3 (cyclin $\delta 3$) in the two-hybrid system.

DETAILED DESCRIPTION OF THE INVENTION

5 The invention provides methods of modifying plant or plant cell development. In the context of the invention, the word 'development' encompasses a wide variety of biological process, including growth, morphogenesis, multiplication, enlargement, differentiation or maturation of a cell or plant. In one aspect, the methods of the invention involve transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, or
10 an anti-sense construct complementary to such a nucleic acid, to produce a transformed plant cell; and, growing the transformed plant cell, or progeny of the transformed plant cell, under conditions wherein the cyclin-dependent kinase inhibitor polypeptide, or the anti-sense construct, is expressed in the transformed plant cell or in the progeny of the transformed plant cell. A 'CDK inhibitor polypeptide' is any polypeptide capable of inhibiting a CDK,
15 preferably a CDK active during development of a plant or plant cell. The growing of the transformed plant cell or progeny of the transformed plant cell may be carried out to produce a transformed plant, such as by regenerating a plant from a transformed culture or by propagating or growing whole plants from transformed plant parts. The cyclin-dependent kinase inhibitor polypeptide, or anti-sense construct, may be expressed to modify the
20 development of the transformed plant or progeny of the transformed plant. The term 'progeny', with reference to a plant, includes progeny produced sexually or asexually (for example by tissue culture-based propagation). The term 'growing' with reference to the transformed cells or plants includes all methods for growing and propagating cells or plants, such as tissue culture or horticultural means of propagating plants or plant parts.

25 In the following detailed description, various examples are set out of particular embodiments of the invention, together with experimental procedures that may be used to implement a wide variety of modifications and variations in the practice of the present invention.

In the context of the present invention, "promoter" means a sequence sufficient to direct transcription of a gene when the promoter is operably linked to the gene. The promoter is accordingly the portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not universally, located in the 5' non-coding regions of a gene. A promoter and a gene are "operably linked" when such sequences are functionally connected so as to permit gene expression mediated by the promoter. The term "operably linked" accordingly indicates that DNA segments are arranged so that they function in concert for their intended purposes, such as initiating transcription in the promoter to proceed through the coding segment of a gene to a terminator portion of the gene. Gene expression may occur in some instances when appropriate molecules (such as transcriptional activator proteins) are bound to the promoter. Expression is the process of conversion of the information of a coding sequence of a gene into mRNA by transcription and subsequently into polypeptide (protein) by translation, as a result of which the protein is said to be expressed. As the term is used herein, a gene or nucleic acid is "expressible" if it is capable of expression under appropriate conditions in a particular host cell.

For the present invention, promoters may be used that provide for preferential gene expression within a specific organ or tissue, or during a specific period of development. For example, promoters may be used that are specific for leaf (Dunsmuir, *et al Nucleic Acids Res*, (1983) 11:4177-4183), root tips (Pokalsky, *et al Nucleic Acids Res*, (1989) 17:4661-4673), fruit (Peat, *et al Plant Mol. Biol*, (1989) 13:639-651; United States Patent No. 4,943,674 issued 24 July, 1990; International Patent Publication WO-A 8 809 334; United States Patent No. 5,175,095 issued 29 December, 1992; European Patent Application EP-A 0 409 629; and European Patent Application EP-A 0 409 625) embryogenesis (U.S. Patent No. 5,723,765 issued 3 March 1998 to Oliver *et al.*), or young flowers (Nilsson *et al.* 1998). Such promoters may, in some instances, be obtained from genomic clones of cDNAs. Depending upon the application of the present invention, those skilled in this art may choose a promoter for use in the invention which provides a desired expression pattern. Promoters demonstrating preferential transcriptional activity in plant tissues are, for example, described in European Patent Application EP-A 0 255 378 and International Patent Publication WO-A 9 113 980.

Promoters may be identified from genes which have a differential pattern of expression in a specific tissue by screening a tissue of interest, for example, using methods described in United States Patent No. 4,943,674 and European Patent Application EP-A 0255378. The disclosure herein includes examples of this aspect of the invention, showing that plant tissues and organs can be modified by transgenic expression of a plant CDK inhibitor.

Non-dividing plant cells may tolerate low level expression of CDK inhibitors, such as *ICK1*, in non-targeted tissues. Thus, the invention may be practiced in some embodiments using tissue specific promoters operably linked to CDK inhibitor encoding sequences, even when the promoter mediates a tolerable basal level of expression in other tissues.

Various aspects of the present invention encompass nucleic acid or amino acid sequences that are homologous to other sequences. As the term is used herein, an amino acid or nucleic acid sequence is "homologous" to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (for example, both sequences function as or encode a cyclin-dependent kinase inhibitor; as used herein, sequence conservation or identity does not infer evolutionary relatedness). Nucleic acid sequences may also be homologous if they encode substantially identical amino acid sequences, even if the nucleic acid sequences are not themselves substantially identical, for example as a result of the degeneracy of the genetic code.

Two amino acid or nucleic acid sequences are considered substantially identical if, when optimally aligned, they share at least about 70% sequence identity. In alternative embodiments, sequence identity may for example be at least 75%, at least 90% or at least 95%. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math* 2: 482, the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, and the computerized implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul *et al.* (1990), *J. Mol.*

Biol. 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at <http://www.ncbi.nlm.nih.gov/>). The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. Initial neighborhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments of the invention, nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

An alternative indication that two nucleic acid sequences are substantially identical is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions. Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/0.1% SDS at 42°C (see Ausubel, *et al.* (eds), 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to

filter-bound sequences under stringent conditions may, for example, be performed with 0.1 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS (see Ausubel, *et al.* (eds), 1989, *supra*). Hybridization conditions may be modified with known methods depending on the sequence of interest (see Tijssen, 1993, *Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategic acid probe assays", Elsevier, New York). Generally, stringent conditions are set at about 5°C lower than the thermal melting point for the specific sequence at a given salt strength and pH.

10 An alternative indication that two amino acid sequences are substantially similar is that one peptide is specifically immunologically reactive with antibodies that are specifically immunoreactive against the other peptide. Antibodies are specifically immunoreactive to a peptide if the antibodies bind preferentially to the peptide and do not bind in a significant amount to other proteins present in the sample, so that the binding of the antibody to the peptide is detectable in an immunoassay and distinguishable from non-specific binding to other peptides. Specific immunoreactivity of anti-peptides may be assessed using a variety of immunoassay formats, such as solid phase ELISA immunoassays for selecting monoclonal antibodies specifically immunoreactive with a protein (see Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York).

25 The cyclin-dependent kinase inhibitors of the present invention, and those encoding those inhibitors, may include non-naturally occurring sequences, such as functionally active fragments of naturally occurring sequences. For example, fragments of ICK1, or amino acid sequences homologous to those fragments, that have cyclin-dependent kinase inhibitory activity may be used in some embodiments of the invention. The invention provides methods for identifying such fragments, for example by deletion mapping of cyclin-dependent kinase inhibitors. As used herein the term "cyclin-dependent kinase inhibitor" therefore includes any polypeptide capable of functioning to inhibit

ned in 0.5 dependent kinase and may be used to modify the growth or development of the plant, the S at 68°C (invention similarly encompasses nucleic acid sequences encoding such polypeptides.

in accordar

As used herein to describe nucleic acid or amino acid sequences the term "heterologous" refers to molecules or portions of molecules, such as DNA sequences, that are artificially introduced into a particular host cell. Heterologous DNA sequences may for example be introduced into a host cell by transformation. Such heterologous molecules may include sequences derived from the host cell. Heterologous DNA sequences may become integrated into the host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination events.

ly identical

The specificity of a CDK inhibitor may be assayed *in vivo*. For example, the *ICK1* coding sequence was fused to a known promoter which directed gene expression in pollen but not in stamen primordia. The transformants are normal and fertile. This result indicates that in specific embodiments of the invention, expression of *ICK1* is not generally toxic to tissues other than the target tissue. Phenotypes may be obtained, for example with the exemplified *AP3-ICK1* transformants, that are due to specific action of the CDK inhibitor, such as *ICK1* protein, on cell division. In such embodiments, the CDK inhibitor, such as *ICK1*, may be used as a specific tool to modify growth or development of meristematic tissues without materially affecting other processes.

1 Spring

In some embodiments, there may be important advantages to using a sequence encoding a CDK inhibitor for genetic engineering in plants, particularly to control selected cell lineages, rather than using genes encoding cytotoxins. In accordance with the invention, the CDK inhibitor action may be made to be specific only to certain cells, avoiding the non-specific destruction of plant cells. This specificity may be achieved partly because non-dividing plant cells in non-targeted tissues may have better tolerance of low level expression of a CDK inhibitor than a cytotoxin. Thus, in accordance with the invention it may be possible to use tissue specific promoters for expressing CDK inhibitors when such promoters still have a tolerable basal level of expression in other tissues. This may usefully expand the range of promoters available for use in the invention, since most tissue-specific promoters have some levels of expression in other tissues in addition to a high level of expression in a

particular tissue. In contrast, expression of a potent cytotoxic gene in one tissue, even at a low concentrations, can have a negative impact on growth and development in other tissues.

In an alternative aspect of the invention, the down-regulation of CDK inhibitors, such as ICK1, may be used to enhance growth during plant development. Such growth enhancement may be tissue-specific. For example, anti-sense oligonucleotides may be expressed to down-regulate expression of CDK inhibitors. The expression of such anti-sense constructs may be made to be tissue-specific by operably linking anti-sense encoding sequences to tissue-specific promoters. Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules, act to block the translation of mRNA by binding to targeted mRNA and inhibiting protein translation from the bound mRNA. For example, anti-sense oligonucleotides complementary to regions of a DNA sequence encoding a CDK inhibitor, such as ICK1, may be expressed in transformed plant cells during development to down-regulate the CDK inhibitor. Alternative methods of down-regulating CDK inhibitor gene expression may include the use of ribozymes or other enzymatic RNA molecules (such as hammerhead RNA structures) that are capable of catalyzing the cleavage of RNA (as disclosed in U.S. Patent Nos. 4,987,071 and 5,591,610). The mechanism of ribozyme action generally involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.

Arabidopsis thaliana "Columbia" may be used as a convenient model system for identifying CDK inhibitors that are useful in various embodiments of the present invention. *Arabidopsis* plants are generally grown in pots placed in growth chambers (20°C 16h/8h of day/night). Other plants may also of course be used in various embodiments of the invention in accordance with known growth and transformation techniques.

Yeast two-hybrid cloning and assay techniques may be used to identify and assess CDK inhibitors useful in the present invention. For example, a cDNA library may be made using poly (A) mRNA isolated from whole plants at different stages of development and cloned in a suitable vector, such as Gal4 TA- (transcription-activation domain) pPC86 (Chevray and Nathans, 1992; available from GIBCO/BRL Life Technologies) or pBI771- a modified pPC86 (Koholmi et al., 1997). The cDNA of the gene (such as *cdc2a*, cyclin $\delta 2$ and

cyclin 83) to be used for screening the library may be cloned in a suitable vector, such as the Gal4 DB- (DNA-binding domain) vector. The yeast strain, such as YPB2 or MaV203, harboring the construct may be transformed using the library DNA.

In one example, for analysis of Cdc2a interactions, a total of 1.8×10^7 transformants were subjected to two-hybrid selection on supplemented synthetic dextrose medium lacking leucine, tryptophan and histidine but containing 5 mM 3-amino-1,2,4-triazole. The selected colonies were assayed for β -galactosidase activity using standard methods. DNAs were isolated from positive clones and used to transform *E. coli*. Clones harboring the TA-fusion cDNAs were identified by PCR and plasmids were then isolated for DNA sequencing (Wang et al., 1997).

Interactions in the yeast two-hybrid system may, for example, be analyzed by either filter assay (Chevray and Nathans, 1992) using X-gal as the substrate or by a quantification assay using ONPG (ortho-nitrophenyl-beta-D-galactoside) as the substrate (Reynolds and Lundlad, 1994). Three or more independent transformants may be used for each interaction.

Standard methods are available for the preparation of constructs for use in identifying and characterizing CDK inhibitors useful in various embodiments of the invention. General molecular techniques may for example be performed by procedures generally described by Ausubel et al. (1995). Alternative equivalent methods or variations thereof may be used in accordance with the general knowledge of those skilled in this art.

In one example, the *AP3* promoter was cloned by the polymerase chain reaction (PCR) from *Arabidopsis thaliana* "Columbia" genomic DNA, on the basis of the published sequence (Irish and Yamamoto, 1995; GenBank Accession U30729). The promoter was cloned in a modified binary vector pBI121 (Clontech). *ICK1* cDNA (SEQ ID NO: 1; Wang et al., 1997) was similarly amplified by PCR and transcriptionally fused with the *AP3* promoter and the chimeric gene ends with a nopaline synthase terminator. As a comparison and to determine the effect of *ICK1* on differentiated cells such as pollen, the same *ICK1* nucleotide sequence used in *AP3-ICK1* fusion was used in fusion with a *Brassica rapa* (*B. campestris*) anther-specific promoter *Bgp1* (Xu et al. 1993; GenBank Accession X68210). The *Bgp1*

promoter has been shown to be able to direct a high level of GUS (beta-glucuronidase) gene expression in the pollen and tapetum of transgenic *Arabidopsis* plants (Xu et al., 1993). The resulting plasmids were introduced into *Agrobacterium tumefaciens* strain GV3101 (bearing helper plasmid pMP90; Koncz and Schell 1986).

5 In accordance with various aspects of the invention, plant cells may be transformed with heterologous nucleic acids. In this context, "heterologous" denotes any nucleic acid that is introduced by transformation. Transformation techniques that may be employed include plant cell membrane disruption by electroporation, microinjection and polyethylene glycol based transformation (such as are disclosed in Paszkowski *et al.* *EMBO J.* 3:2717 (1984);
10 Fromm *et al.*, *Proc. Natl. Acad. Sci. USA* 82:5824 (1985); Rogers *et al.*, *Methods Enzymol.* 118:627 (1986); and in U.S. Patent Nos. 4,684,611; 4,801,540; 4,743,548 and 5,231,019), biolistic transformation such as DNA particle bombardment (for example as disclosed in Klein, *et al.*, *Nature* 327: 70 (1987); Gordon-Kamm, *et al.* "The Plant Cell" 2:603 (1990); and in U.S. Patent Nos. 4,945,050; 5,015,580; 5,149,655 and 5,466,587); *Agrobacterium*-
15 mediated transformation methods (such as those disclosed in Horsch *et al.* *Science* 233: 496 (1984); Fraley *et al.*, *Proc. Nat'l Acad. Sci. USA* 80:4803 (1983); and U.S. Patent Nos. 4,940,838 and 5,464,763).

Transformed plant cells may be cultured to regenerate whole plants having the transformed genotype and displaying a desired phenotype, as for example modified by the
20 expression of a heterologous CDK inhibitor during growth or development. A variety of plant culture techniques may be used to regenerate whole plants, such as are described in Gamborg and Phillips, "Plant Cell, Tissue and Organ Culture, Fundamental Methods", Springer Berlin, 1995); Evans *et al.* "Protoplasts Isolation and Culture", Handbook of Plant Cell Culture, Macmillian Publishing Company, New York, 1983; or Binding, "Regeneration of Plants,
25 Plant Protoplasts", CRC Press, Boca Raton, 1985; or in Klee *et al.*, *Ann. Rev. of Plant Phys.* 38:467 (1987).

Standard techniques may be used for plant transformation, such as transformation of *Arabidopsis*. In one example, the *AP3-ICK1* and *Bgp1-ICK1* constructs were tested in *A. thaliana* by *in planta* transformation techniques. Wild type (WT) *A. thaliana* seeds of ecotype

“Columbia” were planted in 4” pots containing soil and plants grown in a controlled growth chamber or greenhouse. The vacuum infiltration method of *in planta* transformation (Bechtold et al., 1993) was used to transform *A. thaliana* plants with overnight culture of *A. tumefaciens* strain GV3101 bearing both the helper nopoline plasmid and the binary construct containing the described chimeric gene. pMP90 is a disarmed Ti plasmid with intact *vir* region acting *in trans*, gentamycin and kanamycin selection markers as described in Koncz and Schell (1986). Following infiltration, plants were grown to maturity and seeds (T1) were collected from each pod individually. Seeds were surface-sterilized and screened on selective medium containing 50 mg/L kanamycin with or without 200-300 mg/L timentin. After about four weeks on selection medium, the non-transformed seedlings died. The transformed seedlings were transferred to soil in pots. Leaf DNA was isolated (Edwards et al., 1991) and analyzed by PCR for the presence of the DNA insertion. Genomic DNA was also isolated and used in Southern hybridization (Southern, 1975) to determine the copy number of the inserted sequence in a given transformant. To determine the segregation, T2 seeds were collected from T1 plants. Wherever the T1 plant was male sterile, crosses were made using the WT *A. thaliana* pollen to obtain seeds. As described, T2 seeds were surface-sterilized and screened on selective medium.

Alternative embodiments of the invention may make use of techniques for transformation of *Brassica*. Such as transformation of *B. napus* cv. Westar and *B. carinata* cv. Dodolla by co-cultivation of cotyledonary petioles or hypocotyl explants with *A. tumefaciens* bearing the plasmids described herein. Transformation of *B. napus* plants may, for example, be performed according to the method by Moloney et al. (1989). Modifications of that method may include the introduction of a 7-day explant-recovery period following co-cultivation, on MS medium with the hormone benzyladenine (BA), and the antibiotic timentin for the elimination of *Agrobacterium*. Transformation of *B. carinata* plants may be performed according to the method by Babic et al. (1998). Cotyledonary petiole explants may be dipped in suspension of *Agrobacterium* bearing the desired constructs and placed on 7-cm filter paper (Whatman no. 1) on top of the regeneration medium for 2 days. After co-cultivation, explants may be transferred onto the selection medium containing 50 mg/L kanamycin. Regenerated green shoots may first be transferred to a medium to allow

elongation and then to a rooting medium all containing 50 mg/L kanamycin. Putative transformants with roots (T0) may be transferred to soil. Genomic DNA may be isolated from developing leaves for PCR and Southern analyses. Seeds (T1) from transgenic plants may then be harvested.

5 Transgenic plants may be observed and characterized for alteration of traits such as petals, male sterility and ability to set seeds. For example, to determine the development of floral organs, flowers at different stages of development may be dissected and examined under a stereomicroscope. Floral samples may also be examined using scanning electron microscope for more defined morphology of floral organ meristems and their development.

10 Genomic clones of sequences encoding putative CDK inhibitors may be cloned using standard techniques. For example, to clone a genomic *ICK1* encoding sequence, genomic DNA may be isolated from two-week old *A. thaliana* seedlings (according to the procedure described by Lohdi et al., 1994). In one example, the genomic sequence spanning the *ICK1* cDNA sequence (SEQ ID NO: 1) was amplified by 30 cycles of PCR using sequence-specific
15 primers with incorporated restriction sites. *Pfu* DNA polymerase (Stratagene), which has a higher replication fidelity than the *Taq* DNA polymerase, may be used. The amplified DNA fragment may be cloned into a suitable vector, such as pGEM5Zf(+) (Promega). Plasmids may then be purified and sequenced.

In one example, an *ICK1* cDNA isolated from the two hybrid screening was cloned in
20 frame into pBI786, a modified His₆-tagged vector derived from pRSETB (Invitrogen) (Wang et al., 1997). Recombinant His₆-ICK1 was purified from *E. coli* using Ni-NTA agarose resin (QIAGEN) according to manufacturer's instructions except that the final washing was with buffer D, pH 6.0 and the protein was eluted with 2 ml buffer D, pH 4.0. The eluent was
renatured by diluting with 10X volume of a renaturing buffer (10 mM Tris pH 7.5, 500 mM
25 NaCl, 400 mM arginine HCl, 20 μM MgCl₂, 20 μM ZnAc and 0.1% Tween 20) and dialysed in the same buffer (500 ml per 2 ml sample) at 4°C overnight. The protein samples may be concentrated with Filtron 10K concentrators. The sample was then dialyzed at 4°C for 3 h against 1000 volumes of the kinase assay buffer (see below) containing 0.4 mM DTT and

each (0.4 µg/ml) of the protease inhibitors soybean trypsin inhibitor, antipain and apotinin. The protein was stored at -80 °C.

Kinase assays may be useful in some aspects of the invention, for example to assay the function of CDK inhibitors on particular kinases. For example, kinases may be purified from *A. thaliana* tissues or cultured *B. napus* cells. Plant materials may be homogenized in 2 mls per gram tissue of ice cold extraction buffer consisting of 25 mM Tris pH 8.0, 100 mM NaCl, 10 mM DTT, 5 mM NaF, 1 mM Na₃VO₄, 1 mM β-glycerophosphate, 2.5 mM EDTA, 400 µg/ml AEBSF [4-(2-aminoethyl)-enzensulfonyl fluoride], 1 µg/ml leupeptin and 1 µg/ml pepstatin. The homogenate was centrifuged at 12,000g at 4°C for 30 min. The supernatants may be used to purify Cdc2-like protein kinases using p13^{suc1}-conjugated agarose beads (Oncogene Sciences). The required amount of supernatant (150 µg protein for each reaction) was added to the beads and tumbled at 4°C for 2 h. The beads may be washed twice in a washing buffer consisting of 50 mM Tris pH 7.4, 250 mM NaCl, 0.1% NP-40, 2.5 mM EDTA, 1 mM DTT and inhibitor cocktail of (in final concentrations) 10 µg/ml apotinin, 10 µg/ml antipain, 10 µg/ml soybean trypsin inhibitor, 10 mM β-glycerophosphate, 1 mM NaF and 0.2 mM Na₃VO₄. Beads may then be washed twice in the kinase assay buffer (50 mM Tris pH 7.4, 10 mM MgCl, 2 mM EGTA, 2 mM DTT and the inhibitor cocktail). For inhibition assays, the recombinant protein was added to the reactions and incubated (tumbling slowly) for 1.5 h at 4°C. The kinase reaction was initiated by adding 1 µg/µl histone H1 (Sigma), 25 µM ATP and 0.05 µCi/ul ³²P-γ-ATP (final concentrations), and stopped after 20 min incubation by adding the sample buffer. Denatured supernatant was resolved by SDS-PAGE.

RNA isolation and northern blotting analysis may be useful in various embodiments of the invention. For example, to analyze *ICK1* expression during plant development, various tissues may be taken from *Arabidopsis* plants. To analyse the effects of ABA and low temperature, seedlings may be treated as described (Wang et al., 1995). Briefly, seedlings (12 days) grown in pots may be cleared of soil with water, then floated in 0.1X strength MS medium without sucrose and hormones. Low temperature treatment was at 5°C for 24 h. ABA treatment was carried out in a solution containing 50 µM ABA. Seedling samples may be removed after various treatment times. Total RNA was isolated using TRIzol reagent

(GIBCO BRL). For northern analysis, the indicated amount of RNA was fractionated in a 1.2% agarose gel and transferred onto Hybond-N+ nylon membrane (Amersham). The RNA was crosslinked to the membrane by UV-light (Stratalinker, Stratagene) and hybridized with ³²P-labeled probes. The membranes may be wrapped and used to expose Hyperfilm MP (Amersham) film. Membranes may be stripped by treating with a boiling solution of 0.1X SSC and 0.1% SDS for 5 min. Quantification of hybridized signal was performed using Molecular Dynamics PhosphorImager and the accompanying software.

In vitro binding assays may be useful in various aspects of the invention, for example to assay the interaction of a CDK inhibitor, or fragments of a CDK inhibitor, and a particular kinase. As an example of such an approach, ³⁵S-Met labeled Cdc2a, CycD3 and ATMPK2 proteins may be expressed from a T7 promoter construct using an *in vitro* coupled rabbit reticulocyte transcription/translation system ('TNT', Promega). Ni²⁺-NTA beads (Qiagen) may be equilibrated and blocked in NETN buffer lacking EDTA (NTN) (Bai et al., 1996), and supplemented with 2 mg/ml BSA. Equilibrated beads may be incubated with His₆-ICK1 (5 µg for each 10 µl beads) in 1 ml of NTN buffer for 2 h with tumbling at 10°C followed by washing with 2 X 1 ml NTN buffer. Binding experiments may be carried out in a total volume of 100 µl NTN containing 10 µl beads, plus 5 µl ³⁵S-Met labeled protein. The binding reaction was incubated at 10°C for 2 h, followed by washing with 3 X 0.5 ml NTN buffer. Washed beads may be eluted with 10 µl SDS-containing denaturing buffer at 100°C for 5 min, and bound ³⁵S-Met labeled proteins analyzed by SDS-PAGE. Gels may be imbedded with a fluorography enhancer ('Amplify', Amersham) prior to drying and exposure to X-ray film.

Deletion constructs may be useful for domain mapping to determine the functional domains of a CDK inhibitor. For example, N-terminal deletion constructs of ICK1 were made using cDNAs with deletions of various lengths from the N-terminal end. The C-terminal deletion constructs were prepared by PCR using *Pfu* DNA polymerase with sequence-specific primers and the resulting DNA fragments were cloned into the yeast two-hybrid vector pBI771 (Kohalmi et al., 1997). The deletion clones may be verified by DNA sequencing. The constructs may be used to transform a suitable yeast strain. In one such example, yeast strain YPB2 harboring either *cdc2a* or *CycD3* cloned in the BD- (binding domain) vector was transformed with deletion constructs. Interactions in the yeast two-hybrid system may then,

for example, be analyzed by X-gal filter assay (Chevray and Nathans, 1992) and by liquid culture assays for relative β -galactosidase activity (for example using the modified procedure of Reynolds and Lundlad, 1994). Three or more independent transformants may be used for each interaction.

5 *Sequence Analyses:* Sequence analyses, including determination of sequence homology, may be performed using a variety of software, such as LASERGENE (DNASTAR). Database searches may also use a variety of software tools, such as the BLAST program (NCBI).

10 *Analysis of CDK inhibitor cDNA Clones and Genomic Sequences:* The yeast two-hybrid system (Fields and Song, 1989; Kohalmi et al., 1997) may be used to identify genes, such as *ICK1*, that encode inhibitor proteins able to interact with the plant cyclin-dependent kinases, such as Cdc2 kinase, for use in the present invention. For example, among the 68 *ICK* (*I*nteractors of *C*dc2 *K*inase) clones identified using Cdc2a as the bait in a yeast two hybrid system (Wang et al., 1997), 55 represented various lengths of *ICK1*, 7 of *ICK2* and 6
15 of *ICK3*. A contig sequence for homologous clones disclosed by the yeast two hybrid assay may be used, as was the contig sequence for *ICK1* cDNA (Wang et al., 1997), to search cDNA and genomic databases at sites such as NCBI (<http://www.ncbi.nlm.nih.gov>) and AtDB (<http://genome-www.stanford.edu/Arabidopsis>), for sequences homologous to those identified by the two-hybrid screen. Two EST clones homologous to the *ICK1* cDNA
20 sequence have been identified in this way. A clone designated 96D15T7 possessed an extra 5' sequence to that of the contig assembled from the two-hybrid cDNA clones. A search of the AtDB database using *ICK1* cDNA (SEQ ID NO: 1) or genomic sequences indicates that the *ICK1* gene sequence is located in a BAC (bacterial artificial chromosome) genomic clone F26B6 (GenBank AC003040), which is 128 kb in length and is identified as being located on
25 *Arabidopsis thaliana* chromosome II between cM 35-45 (<http://genome-www3.stanford.edu/cgi-bin/AtDB/SeqRIMap?clone=F26B6>).

Specific PCR primers may be synthesized and used to clone the genomic sequence spanning the entire coding region of a CDK inhibitor gene. For *ICK1*, three independent clones harboring the genomic sequence were identified in this way, sequenced and found to

be identical. Alignment of *ICK1* genomic sequence with the *ICK1* cDNA sequence (SEQ ID NO: 1; GenBank U94772, Wang et al., 1997) reveals three introns. The genomic sequence in the exon regions is identical to the contig of cDNA clones except at nucleotide position 318, which is a T instead of a G as in the reported cDNA sequence (Wang et al., 1997; a majority of the cDNA clones had a G, while other clones had a T at this position). The existence of a T at this position in genomic DNA was verified by sequencing additional genomic clones. The longest open reading frame in the *ICK1* cDNA sequence (SEQ ID NO: 1) predicts a polypeptide of 191 amino acids (SEQ ID NO: 2; Wang et al., 1997). There is an in-frame translation STOP codon 12 nucleotides upstream of the first ATG. In addition, an in-frame translation termination codon was found 30 nucleotides down stream of the predicted termination codon.

CDK inhibitor in vitro assays: *In vitro* kinase assays may be used to demonstrate that a recombinant putative CDK inhibitor, such as ICK1 protein, is an effective inhibitor of plant Cdc2-like kinases. Plant CDK inhibitors may not inhibit CDK from mammalian and yeast cells (Wang et al., 1997). For example, recombinant ICK1 is effective *in vitro* in inhibiting the histone H1 kinase activity of p13^{suc1}-associated kinases from cultured cells of heterologous *Brassica napus*. In addition, it also inhibits the activity of such kinases from *A. thaliana* seedlings, leaves and floral tissues *in vitro*.

Expression of CDK inhibitors: The expression of a CDK inhibitor in particular plant tissues may be assayed to determine, for example, whether that CDK inhibitor will have utility as a division or growth modulator when expressed in such tissues. For example, the expression of *ICK1* was analyzed in several different plant tissues. In general, the transcript abundance of *ICK1* was relatively low and showed low degrees of variation compared with the housekeeping genes such as *TUA4* (a tubulin- α gene) and *GAPDH* (glyceraldehyde phosphate dehydrogenase) of *A. thaliana*. When leaves from plants of different ages were compared, the *ICK1* level in sample L5 (for leaves of 5-week plants) was slightly higher. To verify the functional role of a putative CDK inhibitor in such tissues, the CDK activity may also be assayed.

Regulation of CDK inhibitors by phytohormones and environmental conditions:

Putative CDK inhibitors may be assayed for suitable CDK inhibitor activity for use in the methods of the invention by a variety of tests. For example, induction of expression of the putative CDK inhibitor gene by abscisic acid (ABA), a phytohormone known to inhibit plant growth (Evans, 1984), and at low temperatures. For example, expression of the putative CDK inhibitor gene, such as *ICK1*, in seedlings, such as *A. thaliana* seedlings, may be analyzed in response to treatments with ABA. For *ICK1*, data from an example assay showed that after 24 h, ABA and low temperature treatments increased *ICK1* transcript levels to about 3 times that of the control (no ABA and at 22°C) in 2-week seedlings. The expression of the putative CDK inhibitor gene may be quantified. For *ICK1*, a correlation coefficient was obtained for the relationship of *cdc2a* level, *ICK1* level and *cdc2a/ICK1* ratio with the Cdc2-like kinase activity. The level of *cdc2a* expression was correlated with the level of Cdc2-like histone H1 kinase activity. The level of *ICK1* expression exhibited a weak negative correlation with kinase activity. The correlation coefficient for the *cdc2a/ICK1* ratio with Cdc2-like kinase activity was similar to that for *cdc2a* with Cdc2-like kinase activity. Such results are consistent with CDK (in this example Cdc2 kinase) inhibitor activity in plant cells.

Direct Interaction of ICK1 with Both Cdc2a and CycD3: CDK inhibitors for use in various aspects of the invention may be identified using a yeast two hybrid screening protocol with a variety of bait fusion protein sequences. For example, *ICK1* was independently cloned in a screen using *A. thaliana* CycD3 as the bait, indicating that *ICK1* interacts with CycD3 in

the two hybrid assay. To provide evidence confirming the interaction of a CDK inhibitor with a target protein of interest, further binding assays may be conducted. For example, to test the interactions of ICK1, *cdc2a* and *CycD3* cDNAs were transcribed and translated in an *in vitro* system. *In vitro* expressed Cdc2a and CycD3 proteins were incubated with recombinant His₆-ICK1 protein expressed in *E. coli*. Cdc2a and CycD3 bound to Ni-NTA beads only after they were incubated with recombinant ICK1. The amount of CycD3 bound to recombinant ICK1 protein was more than the control protein ATMPK2 which showed little binding despite the much higher input used. These results demonstrate that ICK1 is able to interact directly with both Cdc2a and CycD3. Similar assays may be used to identify CDK inhibitors capable of interacting with other cellular targets.

Mapping the Domains for ICK1 Interaction with Cdc2a and CycD3: The regions of a CDK inhibitor that are functionally involved in interactions with other proteins may be mapped by deletion mapping using a variety of techniques, such as the yeast two-hybrid system and variations thereof. Such *in vitro* assay results may be verified by *in vivo* tests, since the persistence of interactions in the two hybrid system may be affected by possible alterations in functionality of plant proteins expressed in yeast. As an example of an *in vitro* assay, to determine the functional significance of the C-terminal domain and other regions of *ICK1*, three N-terminal and three C-terminal deletion mutants were assessed for their interactions with Cdc2a and CycD3 in the two-hybrid system. Overall, β -galactosidase marker gene activation in the two hybrid system was stronger for the interaction of all ICK1 constructs with CycD3 compared to Cdc2a, indicative of a stronger or more persistent interaction between ICK1 and CycD3 in the two-hybrid system. Major shifts in β -galactosidase activity were observed when amino acid regions 3-72, 109-153 and 176-191 were deleted. An increase in activity was observed upon deletion of amino acids 3-72. In pairwise comparison, the deletion of amino acid regions 3-72, 73-108, 163-175 or 153-162 had comparable effects on the interactions of ICK1 with Cdc2a versus CycD3, as reflected by the marker gene expression, while the deletions of amino acid regions 109-153 and 176-191 had clearly differential effects. The most significant reduction in β -galactosidase activity for the interaction of ICK1 with CycD3 resulted from the deletion of amino acids 109-153, whereas the deletion of amino acids 176-191 had a more detrimental effect on the interaction

with Cdc2a. The functional importance of a portion of a CDK inhibitor may also be assayed by analyzing the portion of cDNA required for the recovery of clones by each bait construct in the two hybrid system. For example, the region spanning amino acids 109-153 of ICK1 for its interaction with CycD3 was supported by the analysis of the minimum cDNA length required for the recovery of clones by each bait construct. With CycD3 as the bait, the shortest *ICK1* cDNA was N-terminal deleted for amino acids 1-129, while with Cdc2a, seven clones with further deletions extending to amino acid 154 were also isolated. Thus, deletions extending beyond amino acid 130 rendered these clones unrecoverable by the two-hybrid screening using CycD3 as the bait. Taken together, the results indicate that, while the C-terminal domain (containing the consensus sequence with p27^{Kip1}) is most important for the interaction with Cdc2a, the amino acid region 109-153 perhaps with the C-terminal domain is important for the interaction with CycD3.

One aspect of the invention utilizes functionally important regions of a CDK inhibitor, such as ICK1, as components of novel CDK inhibitors. As outlined above, the functionally important regions of a CDK inhibitor may be determined through routine assays.

Alternatively, randomly selected portions of a CDK inhibitor may be selected for use in routine assays to determine whether the selected region is capable of functioning as a CDK inhibitor in the context of the present invention. In various embodiments, regions of ICK1 may be used, such as the 109-153 region and/or the 163-191 region, with or without additional regions from ICK1 or other CDK inhibitors, provided the recombinant protein meets the functional requirements of the present invention (which may be determined through routine screening of functionality).

Arabidopsis transformation with ICK1 constructs: A wide variety of transformation techniques may be used in accordance with the invention to introduce CDK inhibitor genes into plants. In one aspect, the invention provides methods of assaying heterologous CDK inhibitor function in a model plant, such as *Arabidopsis*. For such assays, in one embodiment, transformation may be carried out by infiltration. For example, seeds (T1 generation) collected from infiltrated *Arabidopsis* plants may be surface-sterilized and placed onto MS medium containing 50 µg/ml kanamycin. The antibiotic timentin may also be included in the medium to prevent any bacterial growth, which could occur due to carrier-over from the infiltration.

The vast majority of germinating seedlings will not be transformed, and will become pale and eventually stop growing, transformed seedlings will be green and display normal growth due to the presence of the selectable marker gene. After 4-5 weeks in the selection medium, transformants may be transferred to soil in pots. In the exemplary embodiment, the presence of the DNA insertion was confirmed by extracting the genomic DNA and then using it for PCR amplification. In one example, while the non-transformed wild-type plant gave a negative signal, all twelve (12) plants selected for their resistance to kanamycin were positive for transforming DNA.

Effect of AP3-ICK1 chimeric gene on petal and stamen development: Various aspects of the invention may be used to obtain a wide variety of phenotypic variations in plant morphology or other characteristics. For example, transformed *A. thaliana* plants carrying the *AP3-ICK1* construct displayed a range of phenotypes with regard to petal and stamen morphology (Table 1). Such variation may be due to the insertion in alternative embodiments of the invention of the CDK inhibitor gene into different sites of the plant genome. In the example of modified petal development using *ICK1*, the plants may be classed into three groups: (1) no visible petals, (2) visible petals but reduced size and (3) visible petals with no apparent difference to those of non-transformed plants (Table 1). In terms of fertility, eleven out of twelve plants were male sterile. These results demonstrate that tissue-specific expression of *ICK1* may be used to produce plants with modified petals and/or with male sterility. In some embodiments, the transgenic plants with male sterility may set seeds after pollination, using pollen from non-transformed plants, indicating that the female reproduction system is unaffected in these male sterile plants. Apart from these specific modifications, these transgenic plants otherwise grew and developed normally.

Table 1. Summary of phenotypes of *A. thaliana* plants transformed with *AP3-ICK1* chimeric gene.

Transformant	Petal	Sterility	Seed setting with WT pollen
#1	Reduced size	Sterile	Yes
#2	No visible petals	Sterile	Yes
#3	Normal	Fertile	self-fertile
#4	Reduced size	Sterile	Yes
#5	Reduced size	Sterile	Yes
#6	No visible petals	Sterile	Yes
#7	Reduced size	Sterile	Yes
#8	No visible petals	Sterile	Yes
#9	No visible petals	Sterile	Yes
#10	No visible petals	Sterile	ND ⁽¹⁾
#11	No visible petals	Sterile	Yes
#12	No visible petals	Sterile	Yes

(1) Not determined

- 5 *Co-Inheritance of the inserted gene and phenotype:* T2 plants may be studied to determine the segregation of the inserted gene and also to verify whether the particular phenotype is co-inherited with the inserted gene. For example, T2 seeds of ICK1

transformants were sterilized and placed onto the selective medium. In one such assay, T2 seeds of one transformant (#2) showed 1:1 ratio of segregation between resistant (99) versus non-resistant (102) seedlings. As transformant #2 was male sterile, the T2 seeds were obtained by crosses using wild type pollen. This ratio indicates that there is one insertion in the genome of this transformant. As expected, T2 plants displayed the same phenotype as the corresponding T1 plants.

Increased ICK1 expression in young floral buds is associated with phenotype changes: To analyze ectopic *ICK1* expression in floral buds of transgenic *AP3-ICK1 Arabidopsis* plants, young floral buds were collected from developing inflorescence and RNA was extracted from the tissues samples of individual plants as described (Wang et al., 1995). The samples were prepared the same way for transgenic *Arabidopsis* plants displaying altered petal and anther phenotypes and for control wild type plants with normal petal and anther development. The RNA blotting and hybridization were performed as described above. The results from northern analysis of *ICK1* expression showed that the transgenic plants which had altered petal and anther development also had a higher level of *ICK1* expression in the young floral buds than the control wild type plants. Similar results were obtained from using both the first generation (T1) and the second generation (T2) transgenic plant.

Effect of ICK1 on differentiated cells such as pollen: Expression of *ICK1* can be directed to more differentiated cells such as pollen, to determine its effect on differentiated cells to compare the effect on cells in proliferative tissue such as stamen primordia. As an example, transgenic plants were obtained using *Bgp1-ICK1* chimeric gene construct. Eighteen (18) such transgenic *Arabidopsis* plants were transferred to soil and grew to maturity. All showed normal development of flower and anthers, unlike transgenic plants with *AP3-ICK1* construct most of which showed petal alteration and male sterility. The *Bgp1-ICK1* plants all set seeds without artificial pollination. As *Bgp1* promoter has been shown to be able to direct a high level of GUS (beta-glucuronidase) gene expression in the pollen and tapetum of transgenic *Arabidopsis* plants (Xu et al., 1993), the observation that no significant male sterility phenotype developed in transgenic *Bgp1-ICK1* plants indicates that a differentiated cell such as pollen can tolerate a moderate level of *ICK1* with no detrimental effect on its function.

Other Transgenic Plants: In accordance with alternative embodiments of the invention, a wide variety of CDK inhibitors may be used to modify a wide variety of plant species. As an example, transgenic *Brassica napus* plants were obtained with *AP3-ICK1* construct. Some of the plants showed much reduced petal size and significant reduction in seed-setting, with one plant showing almost complete sterility. The transgenic *Brassica* phenotypes were consistent with the pattern of *AP3* promoter-directed gene expression, i.e. stronger expression in petal and stamen primordia and possibly low levels of expression in the inner integument or ovule (Day et al., 1995). Of fifty-two primary transformants, four showed altered petal development while other transformed plants showed normal petal development and seed-setting. For plants showing poor seed-setting, seeds were obtained by crosses with non-transformed wild-type *B. napus* plants. The inheritance of the altered phenotype was evident in progeny plants. For example, seven of eight progeny plants from one original transformant continued to display the alterations in petal development and three of the eight plants had reduced seed-setting (fertility). Petal growth in early flowers was more significantly affected than in late flowers. Transgenic *B. carinata* plants were also obtained, and phenotypic changes in petal development, similar to transgenic *B. napus* plants, were observed. These results show clearly that *ICK1* can function in a heterologous *Brassica* plant and can be used to modify the growth and development of specific tissues or organs.

As yet another example, transgenic *B. napus* plants were obtained with a chimeric gene construct consisting of the *Bgpl* promoter and *ICK1*. Of over forty putative transformants obtained, four showed reduced seed setting. The degree of reduction varied from an amount of about half the seed-setting in normal plants (in term of number of seeds per pods) to nearly complete sterility. Northern blot analysis showed a strong expression of *ICK1* in the anther of a transgenic plant with male sterile phenotype (see below), suggesting that although moderate to low levels of expression did not affect the fertility, a higher level of expression could result in a sterile phenotype. It is also noted that none of the 18 *Arabidopsis* transformants showed any sterile phenotype with this construct. The absence of sterility among *Arabidopsis* transformants could be attributed to the difference in gene expression mediated by the *Bgpl* promoter in different species, indicating that routine experimentation may be necessary to identify suitable promoters, and other control elements, for use in

alternative embodiments of the invention. For example, the *Bgp1* promoter, which is from *B. rapa* (*B. campestris*) (Xu et al., 1993), may be more effective in activating transgenic *ICK1* expression in *B. napus* than in *A. thaliana* plants. The results in *Brassica* are indicative of the fact that it may be desirable in alternative embodiments to select promoters that mediate very strong expression of the CDK inhibitor gene, such as *ICK1*, during pollen/anther development, in order to optimize the occurrence of sterility. In addition, it may be desirable in some embodiments to mediate expression of the CDK inhibitor gene, such as *ICK1*, at earlier stages of microspore development before and during the last mitosis and preferably before and during meiosis, in order to produce more male sterile transgenic plants.

The expression of *ICK1* in transgenic *B. napus* plants was analysed by northern hybridization using ³²P-labeled *ICK1* cDNA as probe. The *Bgp1* promoter has previously been shown to direct strong exogenous GUS reporter gene expression in pollen of *A. thaliana* and *Nicotiana tobacum* (Xu et al., 1993). This example illustrates expression analysis for transgenic *B. napus* plants harboring *Bgp1-ICK1* constructs. RNA samples were isolated from the leaf and mature anthers of a transgenic plant showing sterility phenotype (significant reduction in seed-setting) and a control *B. napus* Westar plant. For each sample, 15 µg of RNA was loaded and separated by electrophoresis. RNA transfer and hybridization were performed as described. There were no significant levels of *ICK1* expression in leaves of both transgenic and control plants as well as in the pollen of the control plant. However, as expected, a strong level of *ICK1* expression was observed in anthers of the transgenic plant. These results indicate that the reduction in fertility is indeed associated with elevated expression in anthers of the transgenic plant.

As another example, *ICK1* expression was analysed in plants transformed by *AP3-ICK1* construct. One *B. napus* plant showed changes in petal development including absence of one to all four petals and smaller petals. RNA samples were isolated from the leaf, sepal, petal, anther and whole young flower of the transgenic plant and the control plant. The only significant *ICK1* expression was shown to be in the petals of the transgenic plants. There was no detectable signal under the conditions used for the tissues from the control plant. These data suggest that the phenotype observed in transgenic *Brassica* plants was due to over-expression of *ICK1* in petals.

In alternative embodiments, other plant CDK inhibitors may be used in transgenic or transient expression for regulating plant or plant cell growth and development. An example is described here.

A cDNA clone *CDKII* (AJ002173, SEQ ID No. 15 and SEQ ID No.16) sharing some sequence similarity with ICK1, ICK2, ICN2, ICN6 and ICN7 (Table 2) was identified from *Chenopodium rubrum* (by Fountain, Renz and Beck, with information available through NCBI databases at <http://www.ncbi.nih.gov>). *C. rubrum* seeds were collected in Saskatchewan, Canada. RNA was isolated from seedlings and leaves. The full-length coding region of *CDKII* cDNA was cloned using RNA RT-PCR. The amplified fragment was cloned in sense orientation with a constitutive promoter and sequenced. The sequence data showed that the cloned cDNA was identical to *CDKII* of *C. rubrum* in the database. The *Agrobacterium* strain harboring an expression construct of *CDKII* was used to transform *Arabidopsis*. Selection for transformants was performed as described elsewhere herein. Significant morphological changes in plant development were observed in over one third of 38 transformants. These results indicate that the expression of *C. rubrum CDKII* may modify the growth and development of *Arabidopsis thaliana*. *Chenopodium* and *Arabidopsis* are phylogenetically rather distant species with *Chenopodium* belonging to the subclass of Caryophyllidae and *Arabidopsis* to the subclass Dilleniidae. The observation that a *Chenopodium* CDK inhibitor functions in *Arabidopsis* in the context of the present invention indicates that diverse plant CDK inhibitors may be used in various aspects of the present invention. Similarly, *ICN2* has been used to transform *A. thaliana* to modify growth and development of that plant, producing transformed plants with distinct phenotypes. Thus, diverse CDK inhibitors may be used in accordance with various aspects of the invention.

Table 2: Percent Identity, using Clustal method with PAM250 residue weight table

ICK1	ICK2	ICN2	ICN6	ICN7	CDKI1	
100	24.3	22.4	24.5	27.0	23.4	ICK1
	100	20.3	19.2	21.9	20.3	ICK2
		100	33.7	27.7	21.9	ICN2
			100	30.7	23.5	ICN6
				100	28.5	ICN7
					100	CDKI1

Interaction of ICK1 with other proteins: CDK inhibitors may be used in various aspects of the invention to interact with a variety of regulatory components, such as other cell cycle proteins. For example, in some embodiments, it may be desirable to target a known regulatory moiety with a CDK inhibitor. Accordingly, in one aspect of the invention, an assay is provided to determine if a CDK inhibitor interacts with a known protein. Such interactions may be analyzed by a variety of assays for protein-protein interactions including the yeast two-hybrid assay (e.g. Phizicky and Fields, 1995; Malmqvist and Karlsson, 1997). For example, the full-length cDNA of the gene to be analyzed may be cloned in a GAL4-binding domain vector (Kohalmi *et al.*, 1997) using PCR and gene specific primers with flanking restriction sites. Such constructs may be used to transform the yeast carrying the CDK inhibitor of interest, such as ICK1 in a GAL4-activation domain vector. Using this approach, for example, the interactions of ICK1 with a number of cell cycle-related genes from *A. thaliana* were examined in accordance with the invention (Table 3). In these examples, the yeast two-hybrid assay results indicate that in particular embodiments of the invention, ICK1 protein may interact with Cdc2a but not with Cdc2b. Similarly, ICK1 may interact with D-class cyclins, CycD1, CycD2 and CycD3, while not interacting with A/B-class mitotic cyclins, CycA2, CycB1 and CycB2 (Table 3). The yeast two-hybrid assay results also indicate that ICK1 may not interact in some embodiments with PCNA, also a cell cycle protein, and ATMAP2, a kinase sharing some similarity with Cdc2 kinase. Results such as these, indicating that ICK1 interacts with the G1 cyclins and Cdc2a but not the mitotic

cyclins and Cdc2b, indicate that a CDK inhibitor, such as ICK1, may in some embodiments be used in the regulation of cell cycle initiation during plant growth and differentiation.

Table 3. Analyses of ICK1 interactions with other proteins in the yeast two-hybrid system

Gene Group Examined	Gene in DB- Vector	Old Name	Interaction with ICK1	
			Filter assay ⁽¹⁾	Quantification ⁽²⁾
Control	vector alone		-	0
Cdc2 kinase	cdc2a		+++	2.65
	cdc2b		-	0
cyclin	cycD1;1	Cyclin 81	+++	3.13
	cycD2;1	Cyclin 82	++++	14.80
	cycD3;1	Cyclin 83	+++++	22.70
	cycA2;2	Cyc3bAt	-	0.03
	cycB1;1	Cyc1At	-	0.06
	cycB2;2	Cyc2bAt	-	0.05
PCNA	PCNAAt		-	0
MAP kinase	ATMAP2		-	0

Other plant CDK inhibitors: Other plant CDK inhibitors and CDK inhibitor genes sharing functional and sequence similarity with ICK1 may be identified using an approach similar to the approach used to isolate *ICK1*, based for example on their interactions with either *Arabidopsis* Cdc2a or a D-class cyclin (e.g. cyclin D3 or cyclin D2). The CDK inhibitors identified in screens using Cdc2a are designated herein as *ICKs* (for Interactors of Cdc2 Kinase) and those identified in screens using cyclins are designated *ICNs* (for Interactors of Cyclin). Some CDK inhibitors may be isolated independently from both types of screens. The sequences of *ICK2* (SEQ ID NO: 6), *ICN2* (SEQ ID NO: 7), *ICN6* (SEQ ID NO: 8), and *ICN7* (SEQ ID NO: 9) are shown in Figs 2 through 6. These genes share at least two functional properties with ICK1: First, all of these genes encode proteins able to interact with either Cdc2a or a D-class cyclin or both. Such interactions may enable them to regulate the activity of plant CDKs in alternative embodiments of the invention. Second, these ICK/ICN proteins all share some sequence similarity in the region of ICK1 that is functionally important in some embodiments for its interaction with Cdc2a and cyclin D3 (discussed above in the section on "domains for ICK1 interactions with Cdc2a and cyclin D3"). These homologous genes or proteins may be used in some embodiments, in a manner similar to ICK1, to modulate plant growth and development. One or more such genes or proteins may be used in some embodiments alone or in combination to provide temporal and spatial regulation of cell cycle initiation and progressing during plant development in accordance with this invention.

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. For example, additional plant cyclin-dependent kinase inhibitor genes useful in regulating morphogenesis may be disclosed using the screening methods of the invention, such genes may share functional homology with *ICK1*, while being sequence-divergent from *ICK1*. The examples herein are illustrative only of various aspects or embodiments of the invention.

REFERENCES

- Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Stuhl K.
(1995) Current Protocols in Molecular Biology, Vols 1, 2 and 3.
- Babic V, Datla RS, Scoles GJ, Keller WA (1998) Development of an efficient
5 *Agrobacterium*-mediated transformation system for *Brassica carinata*. *Plant Cell Rep* 17:
183-188
- Bai C, Sen P, Hofmann K, Ma L, Goebel M, Harper JW, Elledge SJ (1996) *SKP1*
connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif,
the F-box. *Cell* 86: 263-274
- 10 Bechtold N, Ellis J, Pelletier (1993) *In planta Agrobacterium*-mediated gene transfer
by infiltration of adult *Arabidopsis thaliana* plants. *C R Acad Sci Paris, Science de la vie/Life*
ciences 316: 1194-1199
- Bell MH, Halford NG, Ormrod JC, Francis D (1993) Tobacco plants transformed with
cdc25, a mitotic inducer gene from fission yeast. *Plant Mol Biol* 23: 445-451
- 15 Brock TG, Kaufman PB (1991) Growth regulators: an account of hormones and
growth regulation. In *Growth and Development*. Plant Physiology, A Treatise, Volume 10.
San Diego: Academic Press, pp. 277-340
- Casaccia-Bonnet P, Tikoo R, Kiyokawa H, Friedrich V Jr, Chao MV, Koff A (1997)
Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent
20 kinase inhibitor p27Kip1. *Genes Dev* 11: 2335-2346
- Chevray PM, Nathans D (1992) Protein interaction cloning in yeast: identification of
mammalian proteins that react with the leucine zipper of Jun. *Proc Natl Acad Sci USA* 89:
5789-5793
- Day CD, Galgoci BF, Irish VF (1995) Genetic ablation of petal and stamen primordia
25 to elucidate cell interactions during floral development. *Development* 121: 2887-2895

- De Veylder L, Segers G, Glab N, Casteels P, Van Montagu M, Inzé D (1997) The *Arabidopsis* Cks1At protein binds the cyclin-dependent kinases Cdc2aAt and Cdc2bAt. *FEBS Lett* 412: 446-452
- 5 Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. *Cell* 82: 675-684
- Doerner P, Jorgensen J-E, You R, Steppuhn J, Lamb C (1996) Control of root growth and development by cyclin expression. *Nature* 380: 520-523
- 10 Durand B, Fero ML, Roberts JM, Raff MC. (1998) p27Kip1 alters the response of cells to mitogen and is part of a cell-intrinsic timer that arrests the cell cycle and initiates differentiation. *Curr Biol* 8: 431-440
- Edwards K, Johnstone C, Thompson C (1991) A simple and rapid method for the preparation of plant genomic DNA for PCR analysis. *Nucleic Acids Res* 19: 1349
- 15 Evans ML (1984) Functions of hormones at the cellular level of organization. In *Hormonal Regulation of Development II. Encyclopedia of Plant Physiology, New Series*, Volume 10 (Scott T. K. ed.). Berlin: Springer-Verlag, pp. 22-79
- 20 Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. *Cell* 85: 733-744
- Ferreira PCG, Hemerly AS, de Almeida Engler J, Van Montagu M, Engler G, Inzé D (1994) Developmental expression of the *Arabidopsis* cyclin gene *cyc1At*. *Plant Cell* 6: 1763-1774
- 25 Ferreira PCG, Hemerly AS, Villarroel R, Van Montagu M, Inzé D (1991) The *Arabidopsis* functional homolog of the p34^{cdc2} protein kinase. *Plant Cell* 3: 531-540

Fields S, Song, O-K (1989) A novel genetic system to detect protein-protein interactions. *Nature* 340: 245-246

Flores-Rozas H, Kelman Z, Dean FB, Pan Z-Q, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J (1994) Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. *Proc Natl Acad Sci USA* 91: 8655-8659

Francis D, Halford NG (1995) The plant cell cycle. *Physiol Plant* 93: 365-374

Gorst JR, John PCL, Sek FJ (1991) Levels of p34^{cdc2}-like protein in dividing, differentiating and dedifferentiating cells of carrot. *Planta* 185: 304-310

Grafi G, Larkins BA (1995) Endoreduplication in maize endosperm: involvement of M phase-promoting factor inhibition and induction of S phase-related kinases. *Science* 269: 1262-1264

Harper JW, Elledge SJ (1996) Cdk inhibitors in development and cancer. *Curr Opin Genet Dev* 6: 56-64

Hemerly AS, Ferreira PCG, de Almeida Engler J, Van Montagu M, Engler G, Inzé D (1993) *cdc2a* expression in *Arabidopsis thaliana* is linked with competence for cell division. *Plant Cell* 5: 1711-1723

Hemerly A, de Almeida Engler J, Bergounioux C, Van Montagu M, Engler G, Inzé D, Ferreira P (1995) Dominant negative mutants of the Cdc2 kinase uncouple cell division from iterative plant development. *EMBO J* 14: 3925-3936

Hindley J, Phear GA (1984) Sequence of the cell division gene *CDC2* from *Schizosaccharomyces pombe*: patterns of splicing and homology to protein kinases. *Gene* 31: 129-134

Hirayama T, Imajuku Y, Anai T, Matsui M, Oka A (1991) Identification of two cell-cycle-controlling *cdc2* gene homologs in *Arabidopsis thaliana*. *Gene* 105: 159-165

- Jacobs TW (1995) Cell cycle control. *Annu Rev Plant Physiol Plant Mol Biol* 46: 317-339
- John PCL, Zhang K, Dong C, Diederich L, Wightman F (1993) p34^{cdc2} related proteins in control of cell cycle progression, the switch between division and differentiation in tissue development, and stimulation of division by auxin and cytokinin. *Aust J Plant Physiol* 20: 503-526
- Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). *Cell* 85: 721-732
- 10 Kohalmi SE, Nowak J, Crosby WL (1997) The yeast two-hybrid system. In *Differentially Expressed Genes in Plants: A Bench Manual Manual* (Hansen E, Harper G, eds), London, Taylor & Francis, pp. 63-82
- Koncz C, Schell J (1986) The promoter of T_L-DNA gene 5 controls the tissue-specific expression of chimeric genes carried by a novel type of *Agrobacterium* binary vector. *Mol Gen Genet* 204: 383-396
- 15 Lörincz AT, Reed SI (1984) Primary structure homology between the product of yeast cell division control gene *CDC28* and vertebrate oncogenes. *Nature* 307: 183-185
- Lees E (1995) Cyclin-dependent kinase regulation. *Curr Opin Cell Biol* 7: 773-780
- Lohdi MA, Ye G-N, Weeden N, Reisch BI (1994) A simple and efficient method for DNA extraction from grapevine cultivars and *Vitis* species. *Plant Mol Biol Rep* 12: 6-13
- 20 Malmqvist M, Karlsson R (1997) Biomolecular interaction analysis: affinity biosensor technologies for functional analysis of proteins. *Curr Opin Chem Biol* 1: 378-83
- Martinez MC, Jorgensen JE, Lawton MA, Lamb CJ, Doerner PW (1992) Spatial pattern of *cdc2* expression in relation to meristem activity and cell proliferation during plant development. *Proc Natl Acad Sci USA* 89: 7360-7364
- 25

- Meyerowitz EM (1997) Genetic control of cell division patterns in developing plants. *Cell* 88: 299-308
- Miao G-H, Hong Z, Verma DPS (1993) Two functional soybean genes encoding p34^{cdc2} protein kinases are regulated by different plant developmental pathways *Proc Natl Acad Sci USA* 90: 943-947
- 5 Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP (1996) The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. *Genes Dev* 10: 3065-3075
- Mizoguchi T, Gotoh Y, Nishida E, Yamaguchi-Shinozaki K, Hayashida N, Iwasaki T, Kamada H, Shinozaki K (1994) Characterization of two cDNAs that encode MAP kinase homologues in *Arabidopsis thaliana* and analysis of the possible role of auxin in activating such kinase activities in cultured cells. *Plant J* 5: 111-122
- 10 Moloney MM, Walker JM, Sharma KK (1989) High efficiency transformation of *Brassica napus* using *Agrobacterium* vectors. *Plant Cell Rep* 8: 238-242
- Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. *Cell* 85: 707-720
- 15 Nasmyth K, Hunt T (1993) Cell cycle. Dams and sluices. *Nature* 366: 634-635
- Nilsson O, Wu E, Wolfe DS, Weigel D (1998) Genetic ablation of flowers in transgenic *Arabidopsis*. *Plant J* 15: 789-804
- 20 Newton RJ (1977) Absciscic acid effects on fronds and roots of *Lemna minor* L. *Amer J Bot* 64: 45-49
- Phizicky EM, Fields S (1995) Protein-protein interactions: methods for detection and analysis. *Microbiol Rev* 59: 94-123

Pines J (1995) Cyclins and cyclin-dependent kinases: a biochemical view. *Biochem J* 308: 697-711

Renaudin J-P, Doonan JH, Freeman D, Hashimoto J, Hirt H, Inzé D, Jacobs T, Kouchi H, Rouzé P, Sauter M, Savouré A, Sorrell DA, Sundaresan V, Murray JAH (1996) Plant Cyclins: a unified nomenclature for plant A-, B- and D-type cyclins based on sequence organization. *Plant Mol Biol* 32: 1003-1018

Reynolds A, Lundblad V (1994) Yeast vectors and assays for expression of cloned genes. In *Current Protocols in Molecular Biology* (Ausubel, F.M. et al, eds), New York, Wiley & Sons, pp. 13.6.1-13.6.4

Robertson JM, Yeung EC, Reid DM, Hubick KT (1990) Developmental responses to drought and abscisic acid in sunflower roots. 2. Mitotic activity. *J Exp Bot* 41: 339-350

Russo AA, Jeffrey PD, Patten AK, Massagué J, Pavletich NP (1996) Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. *Nature* 382: 325-331

Sauter M, Mekhedov SL, Kende H (1995) Gibberellin promotes histone H1 kinase activity and the expression of cdc2 and cyclin genes during the induction of rapid growth in deepwater rice internodes. *Plant J* 7: 623-632

Segers G, Gadisseur I, Bergounioux C, de Almeida Engler J, Jacquemard A, Van Montagu M, Inzé D (1996) The *Arabidopsis* cyclin-dependent kinase gene *cdc2bAt* is preferentially expressed during S and G₂ phases of the cell cycle. *Plant J* 10: 601-612

Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 9: 1149-1163

Soni R, Carmichael JP, Shah ZH, Murray JAH (1995) A family of cyclin D homologs from plants differentially controlled by growth regulators and containing the conserved retinoblastoma protein interaction motif. *Plant Cell* 7: 85-103

Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J Mol Biol* 98: 503-517

Steward GR, Smith H (1972) Effects of abscisic acid on nuclei acid synthesis and the induction of nitrate reductase in *Lemna polyrhiza*. *J Exp Bot* 23Z: 875-885

5 Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. *Nature* 369: 574-578

Wang H, Datla R, Georges F, Loewen M, Cutler AJ (1995) Promoters from *kin1* and *cor6.6*, two homologous *Arabidopsis thaliana* genes: transcriptional regulation and gene expression induced by low temperature, ABA, osmoticum and dehydration. *Plant Mol Biol*
10 28: 605-617

Wang H, Fowke LC, Crosby WL (1997) A plant cyclin-dependent kinase inhibitor gene. *Nature* 386: 451-452

Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T (1996) Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle
15 progression, postnatal liver development and regeneration. *Genes Dev* 10: 245-260

Xu H, Davies SP, Kwan BY, O'Brien AP, Singh M, Knox RB (1993) Haploid and diploid expression of a *Brassica campestris* anther-specific gene promoter in *Arabidopsis* and tobacco. *Mol Gen Genet* 239: 58-65

Yan Y, Frisen J, Lee MH, Massague J, Barbacid M (1997) Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse
20 development. *Genes Dev* 11: 973-983

Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ (1997) Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. *Nature* 387: 151-
25 158.

What is claimed is:

1. A method of modifying plant cell development comprising transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide to produce a transformed plant cell; and, growing the transformed plant cell or progeny of the transformed plant cell under conditions wherein the cyclin-dependent kinase inhibitor polypeptide is expressed in the transformed plant cell or in the progeny of the transformed plant cell.
2. The method of claim 1 wherein growing of the transformed plant cell or progeny of the transformed plant cell is carried out to produce a transformed plant.
3. The method of claim 2 wherein the cyclin-dependent kinase inhibitor polypeptide is expressed to modify the development of the transformed plant or progeny of the transformed plant.
4. The method of any one of claims 1 through 3, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor is homologous to *ICK1*.
5. The method of any one of claims 1 through 3, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor is *ICK1*.
6. The method of any one of claims 1 through 5, wherein the cyclin-dependent kinase inhibitor polypeptide is homologous to *ICK1*.
7. The method of any one of claims 1 through 5, wherein the cyclin-dependent kinase inhibitor polypeptide is *ICK1*.
8. The method of any one of claims 1 through 7, wherein the plant is a member of the Cruciferae family.
9. The method of any one of claims 1 through 7, wherein the plant is a member of the *Brassica* genus.

10. The method of any one of claims 1 through 9, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide is operably linked to a tissue-specific promoter.
11. The method of claim 10, wherein the tissue-specific promoter is homologous to the *AP3* promoter.
12. The method of claim 10, wherein the tissue-specific promoter is the *AP3* promoter.
13. The method of any one of claims 10 through 12, wherein the tissue-specific promoter mediates expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide in petal and stamen primordia.
14. The method of any one of claims 2 through 13 wherein the development of the transformed plant is modified so that the plant is male sterile.
15. The method of any one of claims 2 through 13 wherein the development of the transformed plant is modified so that petals on the transformed plant are altered or absent.
16. A transgenic plant comprising an expressible heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide capable of inhibiting a cyclin-dependent kinase, wherein the heterologous nucleic acid is introduced into the transgenic plant, or an ancestor of the transgenic plant.
17. The transgenic plant of claim 16 wherein the heterologous nucleic acid is introduced into the transgenic plant by the method of any one of claims 1 through 15.
18. A method of modifying plant cell development, wherein the plant cell comprises a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, comprising transforming a plant cell with an anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide, to produce a transformed plant cell; and, culturing the transformed plant cell or progeny of the transformed plant cell under conditions wherein the anti-sense nucleic acid is

transcribed to inhibit expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide in the transformed plant cell or in the progeny of the transformed plant cell.

19. The method of claim 18 wherein culturing the transformed plant cell or progeny of the transformed plant cell is carried out to regenerate a transformed plant.

20. The method of claim 19 wherein the anti-sense nucleic acid is expressed to modify the development of the transformed plant or progeny of the transformed plant.

21. A transgenic plant comprising:

a nucleic acid encoding a cyclin-dependent kinase inhibitor; and,

a heterologous anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor;

wherein the heterologous anti-sense nucleic acid is introduced into the plant, or an ancestor of the plant, by the method of any one of claims 18 through 20.

22. A plant comprising a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor that is expressed during development of the plant to modify development of the plant.

23. The plant of claim 22, wherein the plant has a recombinant genome and the heterologous nucleic acid is integrated into the recombinant genome.

24. A plant comprising:

a nucleic acid encoding a cyclin-dependent kinase inhibitor;

and a heterologous anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor;

wherein the anti-sense nucleic acid is transcribed during development of the plant to inhibit the expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor, to modify development of the plant.


- 5 25. A plant tissue comprising a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor that is expressed during the development of a plant from the tissue to modify the development of the plant.
26. The plant tissue of claim 25 wherein the tissue is selected from the group consisting of a seed and a flower.
- 10 27. The use of a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor to modify the development of a plant.
28. The use of a heterologous anti-sense nucleic acid complementary to a nucleic acid encoding a cyclin-dependent kinase inhibitor to modify the development of a plant.
- 15 29. A method of growing a modified plant, wherein the plant comprises a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, the method comprising growing the plant under conditions so that the cyclin-dependent kinase inhibitor polypeptide is expressed during the growth of the plant to modify the development of the plant.
- 20 30. A method of growing a modified plant, wherein the plant comprises a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide and the plant further comprises a heterologous anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide, the method comprising growing the plant under conditions so that the anti-sense nucleic acid is transcribed during growth of the plant to inhibit the expression of the cyclin-dependent kinase inhibitor and to modify the development of the plant.
- 25 31. A method of modifying the development of a plant comprising:

identifying a nucleic acid homologous to *ICK1* that encodes a cyclin-dependent kinase inhibitor active in the plant;

transforming a plant cell with nucleic acid homologous to *ICK1* to produce a transformed plant cell; and,

5 regenerating the plant from the transformed plant cell under conditions wherein the cyclin-dependent kinase inhibitor is expressed during regeneration of the plant to modify the development of the plant.

A



B

ATCTCTCTCTCTCACAGAGATTGTAACCTTCACGCACACGTAACCTAAATCGAAGATGGTG 60
 M V 2
 AGAAAATATAGAAAAGCTAAAGGAATTGTAGAAGCTGGAGTTTCGTCAACGTATATGCAG 120
 R K Y R K A K G I V E A G V S S T Y M Q 22
 CTACGGAGCCGGAGAATTGTTTATGTTAGATCGGAAAAATCAAGCTCTGTCTCCGTCGTC 180
 L R S R R I V Y V R S E K S S S V S V V 42
 GGTGATAATGGAGTTTCGTCTCTTGTAGTGAAGCAATGAATATAAGAAGAAAGAATTA 240
 G D N G V S S S C S G S N E Y K K K E L 62
 VI VII
 ATACATCTGGAGGAGGAAGATAAAGATGGTGACACTGAAACGTCGACGTATCGACGGGGT 300
 I H L E E E D K D G D T E T S T Y R R G 82
 ACGAAGAGGAAGCTTTTTGAAAATCTGAGAGAGGAGGAGAAAGAAGAATTAAGTAAATCC 360
 T K R K L F E N L R E E E K E E L S K S 102
 ATGGAGAATTATTCATCGGAATTTGAATCGGCGGTTAAAGAATCGTTAGATTGTTGTTGT 420
 M E N Y S S E F E S A V K E S L D C C C 122
 AGCGGGAGGAAAAACGATGGAGGAGACGGTGACGGCGGAGGAGGAGAGAAGGCCAAATTG 480
 S G R K T M E E T V T A E E E E K A K L 142
 ATGACGGAGATGCCAACGGAATCGGAAATTGAAGATTTTTTGTGGAAGCTGAGAAACAA 540
 M T E M P T E S E I E D F F V E A E K Q 162
 VIII
 CTCAAAGAAAAATTCAAGAAGAAGTACAATTTTCGATTTTCGAGAAGGAGAAGCCATTAGAA 600
 L K E K F K K K Y N F D F E K E K P L E 182
 GGACGTTACGAATGGGTAAAGTTAGAGTGAAGAAGAAGAAGAAGTTTATGGTTTTTTTTT 660
 G R Y E W V K L E . 191
 TAACTTTTTAGATTTTAAATATTTTCAGGGAATAAGTTAATTTTATTTTGTGATTGGA 720
 TATAAGATTGTAGGAGGAATGTTTTTAGAAGTACGAAATTGCACAGAAAAGAAGAAAG 780
 CTTTTTAACAGAATTTTAGAGCCCAGAAAAGTCGTGTCTTTTAGCTCTACTTTTACCTCTT 840
 CTTTGAATCTTGTGTATCTTTTAGCATATTCTTTAGTACAATTTTATGTTTTTGGTGAAT 900
 GATA* 905

Characterization of cDNA (Wang et al., 1997) and genomic sequences of *ICK1*.
 (A). Genomic organization *ICK1*. Open bars represent exons and filled bars, introns.
 (B). Features of cDNA sequence and deduced amino acid sequence.

Figure 1

```

61 ACGTATATGCAGCTACGGAGCCGGAGAATTGTTTATGTTAGATCGGAAAAATCAAGCTCT Ick1.seq
3 ACGTATATGCAGCTACGGAGCCGGAGAATTGTTTATGTTAGATCGGAAAAATCAAGCTCT ICK1b.seq
6 [REDACTED]GATTGTTT[REDACTED]TAG [REDACTED] ICK1c.seq

121 GTCTCCGTCGTCGGTGATAATGGAGTTTCGTCGTCCTTGTAGTGAAGCAATGAATATAAG Ick1.seq
63 GTCTCCGTCGTCGGTGATAATGGAG [REDACTED] ICK1b.seq
18 [REDACTED] ICK1c.seq

181 AAGAAAGAATTAATACATCTGGAGGAGGAAGATAAAGATGGTGACACTGAAACGTCGACG Ick1.seq
88 [REDACTED] ICK1b.seq
18 [REDACTED] ICK1c.seq

241 TATCGACGGGGTACGAAGAGGAAGCTTTTTGAAAATCTGAGAGAGGAGGAGAAAGAAGAA Ick1.seq
88 [REDACTED] ICK1b.seq
18 [REDACTED]GGGTACGAAGAGGAAGCTTTTTGAAAATCTGAGAGAGGAGGAGAAAGAAGAA ICK1c.seq

301 TTAAGTAAATCCATGGAGAATTATTCATCGGAATTTGAATCGGCGGTTAAAGAATCGTTA Ick1.seq
88 [REDACTED]AATTATTCATCGGAATTTGAATCGGCGGTTAAAGAATCGTTA ICK1b.seq
70 TTAAGTAAATCCATGGAGAATTATTCATCGGAATTTGAATCGGCGGTTAAAGAATCGTTA ICK1c.seq

361 GATTGTTGTTGTAGCGGGAGGAAAACGATGGAGGAGACGGTGACGGCGGAGGAGGAGGAG Ick1.seq
130 GATTGTTGTTGTAGCGGGAGGAAAACGATGGAGGAGACGGTGACGGCGGAGGAGGAGGAG ICK1b.seq
130 GATTGTTGTTGTAGCGGGAGGAAAACGATGGAGGAG [REDACTED]GAGGAG ICK1c.seq

421 AAGGCGAAATTGATGACGGAGATGCCAACGGAATCGGAAATTGAAGATTTTTTGTGGAA Ick1.seq
190 AAGGCGAAATTGATGACGGAGATGCCAACGGAATCGGAAATTGAAGATTTTTTGTGGAA ICK1b.seq
172 AAGGCGAAATTGATGACGGAGATGCCAACGGAATCGGAAATTGAAGATTTTTTGTGGAA ICK1c.seq

461 GCTGAGAAACAACTCAAAGAAAAATTCAAGAAGAAGTACAATTTTCGATTTTCGAGAAGGAG Ick1.seq
250 GCTGAGAAACAACTCAAAGAAAAATTCAAGAAGAAGTACAATTTTCGATTTTCGAGAAGGAG ICK1b.seq
232 GCTGAGAAACAACTCAAAGAAAAATTCAAGAAGAAGTACAATTTTCGATTTTCGAGAAGGAG ICK1c.seq

541 AAGCCATTAGAAGGACGTTACGAATGGGTAAAGTTAGAGTGAAGAAGAAGAAGAAGTTTA Ick1.seq
310 AAGCCATTAGAAGGACGTTACGAATGGGTAAAGTTAGAGTGAAGAAGAAGAAGAAGTTTA ICK1b.seq
292 AAGCCATTAGAAGGACGTTACGAATGGGTAAAGTTAGAGTGAAGAAGAAGAAGAAGTTTA ICK1c.seq

601 TGGTTTTTTTTTAACTTTTTTAGATTTTAATATTTTCAGGGAATAAGTTAATTTTATTTTG Ick1.seq
370 TGGTTTTTTTTTAACTTTTTTAGATTTTAATATTTTCAGGGAATAAGTTAATTTTATTTTG ICK1b.seq
352 TGGTTTTTTTTTAACTTTTTTAGATTTT ICK1c.seq

661 TTGATTTGGAAATATAAGATTGTAGGAGGAATGTTTTAGAAGTACGAAATTGCACAGA Ick1.seq
430 TTGATTTGGAAATATA ICK1b.seq
379 ICK1c.seq

```

Alignment of *ICK1* cDNA sequence with *ICK1b* and *ICK1c* showing the differences

Figure 2

GTGGAATCTAGGATAATTCTGTCTCCGTGTGTACAGGCGACGAATCGCGGTGGAATTGTG
GCGAGAAATTCAGCAGGAGCGTCGGAGACGAGTGTTGTTATAGTACGACGGCGAGATTCT
CCTCCGGTTGAAGAACAGTGTCAAATCGAAGAAGAAGATTCGTCCGTTTCGTGTTGTTCT
ACATCGGAAGAGAAATCGAAACGGAGAATCGAATTTGTAGATCTTGAGGAAAATAACGGT
GACGATCGTGAAACAGAAACGTCGTGGATTTACGATGATTTGAATAAGAGTGAGGAATCG
ATGAACATGGATTCTTCTTCGGTGGCTGTTGAAGATGTAGAGTCTCGCCGCAGGTAAAGG
AAGAGTCTCCATGAGACGGTGAAGGAAGCTGAGTTAGAAGACTTTTTTCAGGTGGCGGAG
AAAGATCTTCGGAATAAGTTGTTGGAATGTTCTATGAAGTATAACTTCGATTTTCGAGAAA
GATGAGCCACTTGGTGGAGGAAGATACGAGTGGGTAAATGAATCCATGAAGAAGACGA
TGATGATAATGATGATCATTGTTTTACCAAAGTACTTATTATTTCTTCTGTAATAAT
CTTTGCTTTGATTTTTCTTTTAACAAAATCCAAATGTAGATATCTTCTCTCGAATAATC
AATAACATGTAATTCAACTTTTGTGTACTTCCTTGAGGTAATTAATTAGATTCGTGTT
TTTCTCGATTAATAAACTATAAGTTTATAACTAAA

cDNA sequence of *ICK2*

Figure 3

3/8

AAAAAAAAAGCAGAGAGAGAGAGCACACAAAAATCCAAGAGAGAAAAAATGAGCGAGAGA
AAGCGAGAGCTTGCAGAAGAAGCTTCAAGCACAAAGCTTCTCACCCTGAAGAAAACGAAG
CTTAATGATTCTTCTGATTCAACCCGACTCTCATGACGTATCGTCTTCGCGGTTTCA
TCTTCTTCGTTGCTTCGTCCGCGGCTTTAGCGTCTGATGAATGTTCCGTTACCATCGGT
GGAGAAGAAAGTGATCAGTCCTCGAGTATCAGCTCCGTTGTTTCACCAGTGAATCGAAA
GAAATCGCGAAGAACAGTTCGTGTTTGGTGTAGATCTGGAGGATCATCAAATCGAAACC
GAAACCGAAACCTCAACATTCATCACCAGCAATTTAGAAAAGAGACGAGTCCAGTGAGT
GAGGGTTTGGGAGAAACGACAACAGAAATGGAATCATCATCGGCAACGAAGAGAAAACAA
CCGGGGGTGAGGAAGACTCCAACGGCGCGGAGATTGAGGATTTGTTCTCGGAGCTAGAG
AGTCAAGACGATAAGAAGAAGCAATTCATAGAAAAGTACAACCTCGATATTGTCAATGAC
GAACCGCTTGAAGGTCGCTACAAGTGGGATCGACTTTAAGCCATCAAAAAGCAAATACCA
TCCATGAAGAAGACAAAAGAAAAATAGGTTTTGTTTTTCGTGGTTAACATTTCCACTTGT
ACAGCTCTAGTCTATTTCTCTTTAAAAACCTATGTTACTAGTTCGTACAAAACAAAACAA
AAAACACGACCTTTATAATGAAATTTCCGATCTTGGCTACTAAA

cDNA sequence of *ICN2*

Figure 4

4/8

CTCTCTCCAGAGAAAACATAATGAGCTTGAGAGAAATGAGCGAAACAAAACCCAGAGA
GATTCTGAGTACGAAGGATCAAACATCAAGAGGATGAGACTCGATGATGATGATGACGTT
TTACGCTCACCAGACGAGAACTCTTTCTTCTTCTTCTTCTTCTCTGGCTTACTCGGTT
TCAGATTCCGGAGGTTTCTGCTCCGTCGCGTTATCTGAAGAAGAAGACGATCATCTAAGC
TCAAGCATCAGCTCTGGTTGTTCCAGCAGCGAAACTAAGGAAATCGCTACTCGTCTTCCA
TTTTCAGATCTGGAGGCTCATGAAATCTCCGAAACCGAAATCTCAACGTTACTCACCAAC
AATTTCAGGAAACAGGGAATTTTCATCAAGCGAGAATCTGGGAGAAACAGCAGAAATGGAC
TCGGCGACGACGGAGATGAGAGATCAGAGAAAGACGGAGAAGAAGAAGAGATGGAAAA
TCACCGACGCGAGGACGAGCTTGATGACTTTTTCTCGGCGGCGGAGAGATACGAACAGAAA
CGATTACAGAAAAGTACAACATCAGCATCGTCAATGATACGCCGCTTGAAGGTCGGTAC
CAGTGGGTTAGTCTGAAACCTTAGAAGCCATGGAAGACAAA

cDNA sequence of ICN6

ATTAAGAGTCTGGTTCAGGTCTCGCGTTGACTCGGTTAACTCGGCTCCTGTAGCTCAG
 AGCTCTAATGAAGATGAATGTTTTGACAATTTCTGTAGTGTCCAAGTTTCTTGTGGTGAA
 AACAGTCTCGGTTTTGAATCAAGACACAGCACAAAGGGAGAGCACGCCTTGTAACTTTGT
 GAGGATATGGAGATCATGGTTACACCAGGGTCTAGCACAGGTCGATGTGCAGAGCAACC
 AAAGAGTACACAAGGGAACAAGATAACGTGATCCCGACCACTAGTGAAATGGAGGAGTTC
 TTTGCATATGCAGAGCAGCAGCAACAGAGGCTATTCATGGAGAAGTACAACCTTCGACATT
 GTGAATGATATCCCCCTCAGCGGACGTTACGAATGGGTGCAAGTCAAACCATGAAGTTCA
 AAAGGAAACAGCTCCAAAAGACATGGTGTGAAGTTAGAGAATTGTGATGGAGTTTAACAG
 AACTAACCAAACATCAGAAATCGTGTAAATCCTTAAGTTAATAATGTGGGTGA

cDNA sequence of *ICN7*

SEQ ID NO. 15: The nucleotide sequence of *Chenopodium rubrum* CDKII
 (GenBank AJ002173)

gcacgagcgaaattcgggtgtaggaggttaaaccagagctcgagactgccctagctatggcggcagctgctactccaac
 ttcgtctccggcgaagaagatcaagaaggttcgaagtcgctgataatattcctcaactaagaagtcgctgaaagaatt
 tgcggcgccggagaatttcgccgaattagaacgacgccgttggaagttgcggcggttgtaggaggaagaggttgcg
 aattgctcgagtagcgaggttaattactacagctaggtcggatttccgccgtcttggtctcaagcaattatgatcagt
 gagtcttagcgagccagaagtagttaaggatgatgatggttgggaaatctacagcagatccagaggttgagagtgtg
 aggcgtcgtcaagcaaaaggagagccatagaacagaagcgagagaagctacaaaattagacgaccaggattatccggcg
 acgaaatcaacggtacagatcaagatgccgtctgattcagaatcgaagaattcttgctggtgctgaaaaagatccca
 gaaacgcttcagcgaaaagtacaatttcgacatagttaaggacgtgccactgaaaggctgttatgattgggtccaataa
 atccatgaataaaacccactggtgatagtgatgatgaatgactgaattctccacaattacgcaaaattagccact
 gaaattgcaaaagtaaatctttaatttagcctttcttttttagcagaagttgatctattctcacaccgaaaaaaaa
 aaaa

SEQ ID NO. 16: The amino acid sequence of *Chenopodium rubrum* CDKII
 MAAAATPTSS PAKKIKKVS SSYNIPQLRS RRKNLSAPEN FAELETTPL
 VAAVVEEEEVANCSSEVIT TARSDFPSC CSSNYDQLSS SEPEVVKDDD
 GLGNRTADPE VESGEASSKQ KESHRTEARE ATKLDDQDYP ATKSTVQIKM
 PSDSEIEEFF AVAEKDLQKR FSEKYNFDIV KDVPLKGRYD WVPINP

Figure 6

Consensus 'Consensus #1': When 60% (3) match the residue of the Consensus show the residue of the Consensus, otherwise show '.'.

Decoration 'Decoration #1': Shade (with black at 40% fill) residues that match the consensus named 'Consensus #1' exactly.

Alignment of deduced amino acid sequences of ICK1, ICK2, ICN2, ICN6 and ICN7

Figure 7

















<u>Bait</u>	<u>ICK1 (Numbers indicate the amino acid positions)</u>	<u>Filter assay</u>	<u>Activity</u>
cdc2a	/		0.0
/	(3-191)		0.0
cdc2a	(3-191)		12.4
cdc2a	(73-191)		40.6
cdc2a	(109-191)		42.6
cdc2a	(154-191)		10.7
cdc2a	(3-175)		0.3
cdc2a	(3-162)		0.3
cdc2a	(3-152)		0.0
cyclin 83	/		0.8
cyclin 83	(3-191)		100.0
cyclin 83	(73-191)		397.3
cyclin 83	(109-191)		480.7
cyclin 83	(154-191)		7.1
cyclin 83	(3-175)		19.9
cyclin 83	(3-162)		2.5
cyclin 83	(3-152)		2.2
ATMPK2	(3-191)		0.0

Figure 8

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 99/00532

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/29 C12N15/82 C07K14/415 G01N33/53 A01N65/00
A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A01H G01N A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 26327 A (HUTCHINSON FRED CANCER RES ;ROBERTS JAMES M (US); COATS STEVEN R () 24 July 1997 (1997-07-24)	1-3,10, 16-30
Y	page 47, line 34 - page 51, line 4; claims 10,13	4-9,31
Y	WANG, H., ET AL.: "Arabidopsis thaliana cyclin-dependent kinase inhibitor protein (ICK1) mRNA, complete cds." EMBL ACCESSION NO. U94772, 29 April 1997 (1997-04-29), XP002067455 the whole document -& WANG, H., ET AL.: "A plant cyclin-dependent kinase inhibitor gene" NATURE, vol. 386, 3 April 1997 (1997-04-03), pages 451-452, XP002054969	4-7,31
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 September 1999

Date of mailing of the international search report

13/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

Interr. Application No
PCT/CA 99/00532

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FOUNTAIN, M.D.: "Chenopodium rubrum G1 cyclin-dependent kinase inhibitor mRNA, complete cds" EMBL ACCESSION NO. AJ002173, 27 November 1997 (1997-11-27), XP002067552 the whole document ---	8,9
A	DOERNER P ET AL: "CONTROL OF ROOT GROWTH AND DEVELOPMENT BY CYCLIN EXPRESSION" NATURE, vol. 380, 11 April 1996 (1996-04-11), pages 520-523, XP002045509 the whole document ---	
A	DOONAN J: "PLANT GROWTH: ROOTS IN THE CELL CYCLE" CURRENT BIOLOGY, vol. 6, no. 7, 1 July 1996 (1996-07-01), page 788/789 XP002045511 the whole document ---	
P,X	WO 99 14331 A (ALMEIDA JANICE DE ;LANDRIEU ISABELLE (BE); VEYLDER LIEVEN DE (BE);) 25 March 1999 (1999-03-25) the whole document -----	1-10,13, 14,16-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. al Application No

PCT/CA 99/00532

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9726327	A	24-07-1997	AU 705640 B	27-05-1999
			AU 1750797 A	11-08-1997
			CA 2242382 A	24-07-1997
			EP 0877796 A	18-11-1998
WO 9914331	A	25-03-1999	AU 9540698 A	05-04-1999